MLリソース：エイズ治療剤[主要サイト]
MLリソース:エイズ治療剤から[主要サイト]部を独立させたもの
http://api-net.jfap.or.jp/ ; by | ●メニュー |
イベント・学会等情報
ご意見・ご要望
NGO情報
相談・検査情報
--- 拠点病院、自治体相談窓口、サポートline
厚生労働省情報
自治体情報
トピックス
日本エイズストップ基金
リンク集
お知らせ
エイズQ&A
予防関連資料室
〜ビデオ、パンフレット等の紹介
エイズＱ＆Ａ / ブロック拠点病院一覧表 / 拠点病院一覧 / ＮＧＯ一覧
都道府県窓口等の一覧 / 保健所一覧
エイズ動向委員会報告 / エイズに関する研究成果等普及啓発 / エイズ対策関係法令
抗ＨＩＶ治療ガイドライン（2000年7月）/ 母子感染マニュアル
エイズ用語辞典 / ２００１年末現在の世界の状況
第１３回国際エイズ会議概要・報告集 / 第６回アジア・太平洋地域国際エイズ会議概要・報告集
- エイズ関係海外文書翻訳資料などを無料公開している。「翻訳：次世代の抗レトロウイルス剤」「HIV/AIDS情報ファイル(4)」「翻訳：小児HIV感染症の治療ガイドライン」等約３０点。 エイズ関連では国内最大のサイト。
L a s t U p d a t e : 1 9 9 9 . 7 . 5
最新ニュースからに抗HIV治療ガイドラインとHIV感染症に関する臨床研究 平成10年度研究報告書 (研究要旨)を追加しました。 関係する読み物に高田昇のエッセイ２本を追加しました。 ｐｄｆ出版に「CP News Letter for hips No.3」と「ヤマゲンさんの抗HIV薬写真」と「ヤマゲンさんの抗HIV療法 総論」と「各論」の４本を追加しました。ＨＩＶ感染症の診断と治療に抗HIV薬との併用注意薬一覧表を追加しました。
CONTENTS
１．中四国エイズセンターの紹介
２．最新ニュースから★
３．エイズＱ＆Ａ
４．HIV感染症の診断と治療'99/06/02
５．エイズ関連用語集
６．関係する読み物 '99/06/29
７．血友病と関連疾患について
８．ｐｄｆ出版★貴重な資料を大量に提供〜Guideline,新薬資料の翻訳など
９．お勧めブックマーク
10．中四国エイズセンターへの手紙 '99/06/29
<イベントカレンダー>
ＨＩＶ感染症の診断と治療
抗HIV薬との併用注意薬一覧表'99/06/02
服薬援助ツール
ＨＩＶ感染症の臨床-総論−★詳細な解説
抗レトロウイルス剤に対する耐性：ＨＩＶ感染症に対する臨床的管理との関連
ＨＩＶ感染症に関する抗ウイルス療法 1997年版
ＨＩＶ ＲＮＡ定量の検査法
ＨＩＶ感染症の口腔病変
AIDS患者におけるCMV網膜炎の治療
エイズにともなう悪性リンパ腫の治療
単純性ヘルペスウイルス感染症の治療
フォスカルネット使用の実際
エイズに関連した消化器疾患
エイズにおける進行性多巣性白質脳症
エイズの肺病変について
ｻｲﾄﾒｶﾞﾛｳｲﾙｽ(CMV)感染症の治療
HIVの血液学的合併症と腫瘍合併症
HIV病における神経合併症の治療
あなたが仕事の上でHIV曝露事故にあったら Ver.1
急性ヒト免疫不全ウイルス1型感染症
抗HIV薬のクラス別副作用（1998年12月1日版）
- 抗ＨＩＶ療法と服薬指導等の指導・解説書、マニュアル類、日本エイズ学会抄録集[第10-12[1998]回]、［厚生省研究班報告］平成１０年度 抗ＨＩＶ治療ガイドライン（1999年３月）など厚生省関係出版物
旧http://www.amsmed.or.jp/acc/
センターの案内
治療方針・方法
患者・感染者読本
抗ＨＩＶ療法と服薬指導
針刺し後のHIV感染防止のための予防服用マニュアル
感染防御マニュアル★消毒等院内感染など★針刺し事故対策| HIV/AIDS感染防御レベル| HIV感染の消毒方法| 感染症患者（ＨＩV）のゴミ廃棄方法| Ｑ＆Ａ
看護読本
センターでの治験情報・募集案内（準備中）
センターでの研修・募集案内
緊急医療情報
お知らせ
［厚生省研究班報告］
ＨＩＶ感染症に関する臨床研究
ＨＩＶの疫学と対策に関する研究
我が国におけるＨＩＶ診療ガイドラインの開発に関する研究
平成１０年度 抗ＨＩＶ治療ガイドライン（1999年３月）★PDF(165KB)厚生省科学研究費補助金研究課題
［厚生省コーナー］
エイズ動向委員会報告
拠点病院リスト
感染症予防に関する法律
サーベイランスのためのHIV感染症/AIDS診断基準
厚生省エイズ疾病対策課関連文書
厚生省医薬安全局関連文書
［関連WWW］
厚生省
医薬品副作用被害救済・研究振興調査機構
HIV WEB DICTIONALY
(厚生省・エイズ治療薬研究班)
Continuing Medical Education(CME)
American Medical Association(AMA)
Centers for Disease Contorol and Prevention(CDC)
World Health Organization(WHO)
The Joint United Nations Programme on HIV/AIDS(UNAIDS)
Strategies to Promote Adherence
HIV感染症の経過
抗HIV療法の目的
抗HIV薬の種類
多剤併用療法における薬剤の組み合わせ
抗HIV療法はいつ開始するのか？
効果的な抗HIV療法を行うには？
服薬開始までのポイント
服薬アセスメントと服薬スケジュール立案
服薬開始後のプロセス
服薬についてのQ&A
全国拠点病院リスト
連絡先
●新着 ・ 改訂 情報
●厚生省からの情報
健康政策局研究開発振興課
●このホームページについて
研究班の目的と概要
●ＩＮＤＥＸ（目次）
ＨＩＶ Ｗｅｂ Ｄｉｃｔｉｏｎａｒｙ
厚生省・エイズ治療薬研究班ホームページ
新着 ・ 改訂情報
厚生省からの情報
健康政策局研究開発振興課
このホームページについて
研究班の組織
ａ．研究班の薬剤供給と情報提供システムの説明
ｂ．研究班が供給する薬剤リスト
ｃ．疾患別治療薬リストと研究班供給薬剤の適応
ｄ．研究班供給薬剤の入手方法と治療成績の報告方法
（各種書式）
ｅ．研究班供給薬剤の説明
ｆ．抗ＨＩＶ薬の種類と用法
ｇ．ＦＤＡに承認されているエイズ関連治療薬
薬剤名イニシャル(A〜D) (E〜G) (I〜N) (P〜S) (S〜Z)
ｈ．ＨＩＶ治療薬の紹介
○Ritonavir（リトナビル）
○MK-639（クリキシバン） １．
MK-639（クリキシバン） ２．
○レトロビルカプセル（ジドブジン）
○ABACAVIR／米国添付文書本文
○エピビルTM錠（ラミブジン錠）／ （工事中）
○ ゼリットカプセル添付文書［ZERIT(stavudine)］
○ホスカルネットナトリウム
◇FOSCAVIR@フォスカヴィール（米国の添付文書・翻訳）
○デノシンカプセル添付文書（日本国内版）
○静注用サイトベン（静注用ガンシクロビル）／
サイトベン（ガンシクロビル・カプセル） （米国の添付文書・翻訳）
○Mycobutin（リファブチンカプセル 米国の添付文書（訳））
○Mycelexトローチ米国の添付文書（訳）
●健康局
中間報告書「同性間性的接触におけるエイズ予防対策に関する検討会」[2003.3.27第７回検討会]
感染症法に基づくエイズ患者・感染者情報（平成14年9月30日〜平成14年12月29日）[2003.1.31]
- 平成１４年１２月２９日現在のＨＩＶ感染者及びＡＩＤＳ患者累計
ＨＩＶ感染者計5,121; ＡＩＤＳ患者計2,549; 凝固因子製剤による感染者計1,431
※死亡者報告数
感染症法施行後の任意報告数（平成11年4月1日〜平成14年12月31日） 151名
エイズ予防法*5に基づく法定報告数（平成元年2月17日〜平成11年3月31日） 596名
凝固因子製剤による感染者の累積死亡者数*6 536名
■その他（検討会、研究会等） −健康局
●ＨＩＶ診療支援ネットワークシステム部会
●同性間性的接触におけるエイズ予防対策に関する検討会
■厚生科学審議会科学技術部会
１５回資料[2003.6.26]
- ２． 厚生労働科学研究費補助金の成果の評価
- ＜先端的厚生科学研究分野＞３−２エイズ対策研究事業
１４回資料[2003.5.29]
- １−３． 厚生労働科学研究費補助金研究事業の概要
- ＜先端的厚生科学研究分野＞エイズ対策研究事業
●エイズ動向委員会報告
- http://api-net.jfap.or.jp/mhw/survey/mhw_survey.htm; 2001-2003
エイズ予防情報ネットの資料として
●エイズ動向委員会報告
- http://www.acc.go.jp/mlhw/mhw_survey/mhw_survey.htm
in 国立国際医療センター：エイズ治療・研究開発センター
平成14年エイズ発生動向年報 （平成14（2002）年1月1日〜12月31日）
抗HIV 治療ガイドライン （2003年3月版）
サーベイランスのためのHIV感染症/AIDS診断基準
リソース２ | RESOURCE2
電子会議２番「エイズボランティアの部屋」で発言・提供された情報を集めています。
リソース３ | RESOURCE3
電子会議３番「エイズ教育」で発言・提供された情報を集めています。
リソース４ | RESOURCE4
電子会議４番「エイズ学会・ニフティ地方会」で発言・提供された情報を集めています。
リソース５ | RESOURCE5
電子会議５番「エイズと報道／出版／文化」で発言・提供された情報を集めています。
リソース６ | RESOURCE6
電子会議６番「薬害エイズをめぐって」で発言・提供された情報を集めています。
リソース12RESOURCE12
電子会議12番「インターネットで探すエイズ情報」で発言・提供された情報を集めています。
リソース15RESOURCE15
電子会議15番「エイズ関連学会・会議・イベント報告室」で発言・提供された情報を集めています。
リソース20RESOURCE20
電子会議20番「心と生活を支える会議室」で発言・提供された情報を集めています。
インターネット上のエイズリソースAIDS/HIV Resource on Internet
インターネット上にあるエイズリソースやホームページを集めています。
ニフティサーブ・エイズフォーラムへダイレクトジャンプDIRECT JAMP to NIFTYSERVE AIDS FRUM
ニフティサーブ・エイズフォーラムへダイレクトにジャンプします。ニフティサーブ会員のみご利用いただけます。
電子会議１番「やっほう☆よろしくね！」
電子会議２番「エイズボランティアの部屋」
電子会議３番「エイズ教育」
電子会議４番「エイズ学会ニフティ地方会」
電子会議５番「エイズと報道／出版／文化」
電子会議６番「薬害エイズをめぐって」
電子会議７番「セクシャリティ：豊かな性を求めて」
電子会議８番「何でも相談室」
電子会議９番「フリートーク」
電子会議10番「FAIDSからのお知らせ <ReadOnly>」
電子会議13番「翻訳プロジェクト会議室」
電子会議14番「ＦＡＱ作成検討会議室」
電子会議15番「エイズ関連学会・会議・イベント報告室」
電子会議20番「心と生活を支える会議室」
が表示されているリンクはハイパーリンクです。クリックするとNIFTY Managerが起動し、NIFTY SERVEの該当サービスへアクセスできます。
| リソース2
| リソース4 | リソース5
| リソース6 | インターネット
|| resource2 | resource4 | resource5
| resource6 | internet |
| GUIDE | RESOURCE
| SPECIAL
"ＬＡＰの活動は財団法人東京都地域福祉財団、財団法人日本エイズストップ基金、フレディマーキュリー協会(FMA)等の助成を受けています。";
ライフ・エイズ・プロジェクト（LAP）はHIV感染者・AIDS患者
への社会的支援活動を行っている非営利団体(NGO)です。
Last modified 9/10/99
LAPお知らせ（更新日8/10/99）…ニュースレター27号無料送付受付中
LAP新着情報（更新日9/10/99）…求められる「援助」の視点〜医療者の新たな取り組み〜
LAP案内・活動紹介
HIV/AIDS基礎知識
ＬＡＰニュースレター（全文掲載）★年６回程度、学会報告、解説、ニュースなど
データライブラリ★文献リスト、エイズ予防法ほか
関連リンク集★
ムービー（LAP紹介動画）
索引（ジャンル・分野別）
●現在ご覧のホームページ（LAP1）は画像を取り外す等データ量を減らしています。
Netscape Ver.2.0以上とShockwaveをご使用の方は「LAP2」にどうぞ。
LAPホームページ2
●
最新のライフ・エイズ・プロジェクト（ＬＡＰ）ニュースレター
第27号（1999.7.1発行）
NEW8/10/99新
LAPニュースレター購読方法のご案内 LAPニュースレター無料送付のご案内
第１回ピア・カウンセリング研修会報告［岡部翔太］
「管理」「指導」から「援助」の視点へ〜医療者の新たな取り組み〜［堀成美］
98年度ボランティア指導者研修会参加報告［清水茂徳］
公衆衛生医からのエッセー「正しい知識」に気をつけよう［JINNTA］
草田コラム「HIV感染は免疫力を高める!?」〜従来のエイズ啓発に潜む「脅し」を読み説く〜［草田 央］
HIV・エイズ関連新聞記事（タイトルのみ）
LAP HOTLINEエイズ電話相談
03-5685-9644
毎週土曜日午後4時〜7時
その他のエイズ・HIV電話相談案内 http://www.bekkoame.ne.jp/~koumei_h/aids/hotline.htm
ライフ・エイズ・プロジェクト（LAP）ホームページは下記にも登録済みです。
通信状況にあわせてご利用下さい。
lapjp［メインサイト］ http://www.lapjp.org/
campus［ミラーサイト、「LAP2」のみ］ http://www.campus.ne.jp/~lap/
ライフ・エイズ・プロジェクト（ＬＡＰ）
〒100-8691 東京中央郵便局私書箱490号
［電話相談］03-5685-9644（毎週土曜16〜19時）
［郵便振替］00290-2-43826「LIFE AIDS PROJECT」
［銀行口座］住友銀行横浜駅前支店 695729（普通）
「ライフ エイズ プロジェクト 代表 清水茂徳」
［電子メール］lap@lapjp.org
GOTOHIV感染者の障害者認定関連情報 NEW7/19/989改
GOTOHIV抗体検査関連 NEW11/29/98改
全国保健所リスト［制作者］草田央 他
GOTO薬害エイズ関連文献等リスト
GOTO薬害エイズ関連年表 ［制作者］草田央
GOTOエイズ拠点病院（全国） NEW11/29/98改
エイズ治療・研究開発センターホームページ
http://www.acc.go.jp/mhw/mhw_kyoten/mhw_kyoten.htm
GOTOエイズ拠点病院関連都道府県文書
GOTOエイズ・HIV関連治療薬情報
GOTO厚生省・エイズサーベイランス情報
GOTOエイズ予防法全文 ［制作者］草田央
GOTO国際エイズ会議バンクーバー現地報告
LAPジャンル別索引
ＬＡＰホームページに掲載されている様々な情報を検索しやすくするために、キーワード毎にリストアップした「ジャンル別索引」です（一部外部とのリンクが張られています）。
順次、登録しています。
GOTO障害者認定関連情報 NEW7/19/99改
GOTO社会保障・福祉関連情報（福祉制度・福祉サービス・ホームヘルパー・障害年金等）
GOTO医療関連情報（治療・服薬援助・アドヒアランス・学会報告・検査・STD等） NEW8/7/99改
GOTOセーフセックス関連情報（セーフェストセックス講座・コンドームの付け方・HIV陽性者のセックス等）
GOTO薬害エイズ関連情報
GOTO草田央著作リスト NEW11/29/98改
GOTO関連書籍紹介
★→リンク切れ
現http://www.who.int/HIV_AIDS/
HIV/AIDSに関する疫学データが主。
●Current Issue HIV/AIDS/STI Figures
Global Surveillance on HIV/AIDS/STI
(including country-specific information)
Country-specific Figures★国別ファクトシート［pdf］
Global Report on STIs
Weekly Epidemiological Record (WER)
●STD Factsheet: Knowledge about HIV/AIDS STI
Sexually Transmitted Infections Factsheet
●Basic facts about STIs
★Nine Guidance Modules on Antiretroviral Treatments★抗ウイルス剤治療ガイド（[June 1998]抗レトロウイルス剤療法の９モジユール）★別掲
Elements about Antiretroviral Treatments addressed mainly to "middle level" decision makers at academic and training institutions, major hospitals and district hospitals. However, in all modules there are issues which may be of concern to technical decision makers in government ministries such as health, planning or finance.
★STI Case Management Course
Seven modules to train health care workers in all elements of STI management
Public Health Approach for STI Prevention and care
English, French and Spanish versions of the two main documents about STIs
●Sexually transmitted diseases: policies and principles for prevention and care●性感染症
UNAIDS/WHO Key Material Geneva 1997 (UNAIDS/97.6) (179 369 bytes pdf)
Fondamentaux - ONUSIDA/OMS (206 362 bytes pdf)
Enfermedades de transmision sexual : policicas y principios de prevencion y asistencia Material Fundamental ONUSIDA/OMS (207 318 bytes pdf)
The Public health approach to STD control May 1998 (193 465 bytes)
●Best Practices Collection - UNAIDS
Covers Points of View, Technical Update,Case Studies,Presentation Graphics and Key Materials
Document Center - UNAIDS
A large collection of documents related to HIV/AIDS and STI covering Economics, Epidemiology, Human Rights, Mother to Child Transmission, Prevention, Strategic Planning, Vaccines, Women and Youth
Sexually Transmitted Infections, Formerly Genitourinary Medicine
This journal publishes regularly peer review papers on Sexual Health, STI and HIV. Its supplement of June 1998 (Vol. 74, Suppl 1) covers recent research in syndromic approach to STI management.
The Lancet - Supplement on Sexually Transmitted Diseases
Published in June 1998 covers STI global estimates recent public health aspects of STIs. The site needs registration (free). Please follow given instructions.
●Case Management Course
★Latest Information
UNAIDS Home Page provides regular updating of world aids campaign and important regional and international meetings.
★ASD Info
About HSI
Case Management Course
★HIV/AIDS STI Links
UNAIDS is cosponsored by
UNDP, UNESCO, UNFPA, UNICEF, WHO and the World Bank. Its objectives are to foster an expanded national
response to the epidemic, to promote strong commitment by governments to an expanded
response, to strengthen and coordinate UN action of HIV/AIDS at the global and national levels, and to identify, develop and advocate international best practice.
●Contact Us
WHO Initiative on HIV/AIDS and Sexually Transmitted Infections (HSI)
20, Avenue Appia, CH-1211 Geneva 27, Switzerland
Phone: +41 22 7914459; Fax: +41 22 7914834
E-Mail : gerbasea@who.ch
http://www.who.int/emc-hiv/
Global surveillance of HIV/AIDS and sexually transmitted diseases (STDs) is a
joint effort of WHO and UNAIDS, guided by the UNAIDS/WHO Working Group on Global
HIV/AIDS and STD Surveillance, initiated in November 1996.
*AIDS epidemic update: December 1998
English 357k
Download the free
*Report on the global HIV/AIDS epidemic - June 1998
*Epidemiological Fact Sheets by Country★国別ファクトデータ［pdf］
WHO EMC | UNAIDS
●WHO Report on the global HIV/AIDS epidemic - June 1998
*The full report is presented in pdf format.(1) as one file of 2mb, or as four smaller files.
English - Full report［pdf; 18頁］
Part one |Part two |Part three |Annex
Also available in a text-only HTML version without figures
*The data detailing estimated and reported global AIDS cases from the
annex are also available in spreadsheets
English - Microsoft Excel v.5 | DIF format
*Relevent data are also presented graphically in a slideshow.
Last updated on 01 December 1998
-------------------------------
English - Full report［pdf; 18頁］の要約部
1998年末HIV保菌者は33.4百万人［前年比+10%］、95%が途上国。 1998年度死亡者は2.5百万人。
●World AIDS Campaign
1999 World AIDS Campaign
Listen, Learn, Live!: World AIDS Campaign with Children and Young People
1998 World AIDS Campaign
Force for Change: World AIDS Campaign with Young People
1997 World AIDS Campaign
Children Living in a World with AIDS.
SidAide 1996 Programme
organised by UNAIDS and Fondation SidAide
28 November to 02 December 1996
Programme SidAide 1996
A new logo
for World AIDS Day 1996
World AIDS Day 1996
One world. One hope
●Conferences
XIII International AIDS Conference
9-14 July, 2000, Durban, South Africa
5th International Congress on AIDS in Asia and the Pacific
23-27 October 1999, Kuala Lumpur, Malaysia
For details contact: Malaysian AIDS Council, email icaap99@pd.jaring.my or Internet: http://www.jaring.my/aidsasia99
The Third International Conference on Healthcare Resource Allocation for HIV/AIDS and Other Life-Threatening Illnesses
October 11-13, 1999, Vienna, Austria
For the first announcement and details of how to submit abstracts please refer to the site address above. UNAIDS is cosponsoring the conference with the International Association of Physicians in AIDS Care (IAPAC).
XIth International Conference on AIDS and STDs in Africa
12-16 September 1999, Lusaka, Zambia
The theme of this conference, of which UNAIDS is one of the cosponsors, is "looking into the future: setting priorities for HIV/AIDS in Africa". There will be five tracks, covering: basic science and diagnosis; clinical science and care; epidemiology, prevention and interventions; socioeconomic, political, ethical, legal and behavioural issues; and HIV/AIDS and the community. Each day the conference will have a specific theme, such as the trends and impact of the epidemic in Africa, and children and AIDS in Africa and mother-to-child transmission.
9th International Conference for People Living with HIV/AIDS
13-19 August 1999, Warszawa, Poland
Conference Secretariat Office:
Polish Foundation for Humanitarian Aid "Res Humanae"
ul. Kopernika 15, 00-259 Warsaw, Poland
tel/fax: +48 22/8260660 8266224
e-mail: resaids@waw.pdi.net
International Symposium on HIV, Leukemia, and Opportunistic Cancers
Marrakech, Morocco, 23-29 May 1999
For details contact Conference Secretariat, International Symposium on HIV, Leukemia, and Opportunistic Cancers, c/o Harvard Institute, 651 Huntington Avenue, Suite 633, Boston, MA 02115, USA, e-mail khensle@hsph.harvard.edu
Third International Conference on Nutrition and HIV Infection - Pathophysiology and Management
22-25 April 1999, Cannes, France
Details from ECOR,
c/o The European Heart House,
2035 route des Colles, Les Templiers,
BP 179,
06903 Sophia Antipolis Cedex, France
Fax: (00-33)4 92 94 76 01
10th International Conference on the Reduction of Harm Related Risk
21-25 March 1999, Geneva, Switzerland
by the IHRA - International Harm Reduction Association
These conferences have facilitated networking around the world, with harm-reduction networks developing in Asia, Central and Eastern Europe, USA and Latin America. The African Harm Reduction Network is soon to be founded and the first tentative steps are being taken to establish a European Harm Reduction Network. It is the conference organizers' intention at the 10th conference to give a prominent place to these networks, not only to enable them to meet and to present themselves to the conference delegates, but most importantly, to give them a prominent place in the programme.
AIDS Conference 1998
Singapore, December 1998
In Singapore the Action for AIDS and the Communicable Disease Centre, Tan Tock Seng Hospital, organized a one-day conference with the theme "Facing the Challenge in Singapore". The opening address, keynote address and 4 plenary lectures can be viewed at this Web site.
4th International Congress on Drug Therapy in HIV Infection
8-12 November 1998, Glasgow, Scotland
by P\S\L Consulting Group Inc.
12th World AIDS Conference
June 28 - July 3 1998, Geneva, Switzerland
organised under the auspices of the International AIDS Society.
See also the Brazilian AIDS & STD Programme site for related information.
The Official Satellite Symposium of the 12th International Conference on AIDS
27-28 June 1998, Geneva, Switzerland
This symposium will provide an international forum to profile best
practices, including models of programme experience to development of
effective and sustainable interventions, successful strategies that
address social, policy and legislative barriers to implementation and
sustainability of HIV prevention, and current research on HIV
prevention and its application for effective and sustainable
interventions.
2nd European Conference on the Methods and Results of Social and Behavioural Research on AIDS
AIDS in Europe
12-15 January, 1998
Xth International Conference on STD/AIDS in Africa
Virtual Press Office, by presspack.com
December 7-11, 1997
Xth International Conference on AIDS & STD in Africa
7-11 December 1997, Abidjan, Cote d'Ivoire.
International Conference on AIDS/STD in Africa
7-11 December 1997, Abidjan, Cote d'Ivoire.
Belgian website
5th Pan-American Conference on AIDS
11th Latin American congress on Sexually Transmitted Diseases
3-6 December 1997, Lima, Peru
4th International Congress on AIDS in the Asia and the Pacific
25-29 October 1997, Manila, Philippines
The Health Action Information Network
3rd International Conference on Biopsychosocial Aspects of HIV Infection
Address by Dr. Peter Piot, Executive Director
22 - 25 June 1997 Melbourne, Australia
3rd International Conference on Home and Community Care for persons living with HIV/AIDS
21-24 May 1997, Amsterdam
11th International Conference on AIDS
7-12 July 1996, Vancouver, Canada
UNAIDS Press Release
11th International Conference on AIDS
Canadian HIV Net
11th International Conference on AIDS
produced by JAMA, the Journal of the American Medical Association
11th International Conference on AIDS
CDC Press Releases from DHAP
July 7-12, 1996, Vancouver, Canada
IXth International Conference on AIDS and STD
10 December 1995, Kampala, Africa
Paris AIDS Summit
1 December 1994
---Home| Search| Site Map| Subscribe| What's New
National Center for HIV, STD and TB Prevention
Divisions of HIV/AIDS Prevention
●Main Topics
Basic Science
Surveillance
Prevention Research
Vaccine Research
Prevention Tools
Treatment
Funding
Testing
Evaluation
Software
Training
●General Information
Basic Statistics
Brochures★パンフレット[別掲]
Conferences
Fact Sheets
FAQs
HIV/AIDS FAX System
HIV/AIDS Information
Links to Other Sites
Media/Campaigns
Publications★別掲
Slide Sets
●CDC Links
About DHAP
STD Prevention
TB Prevention
NCHSTP Home Page
CDC Home Page
CDC NPIN Home Page
Employment at CDC
●Headlines:
>> 1999 World AIDS Day - "Listen, Learn, Live!" (December 1, 1999)
>> National HIV Testing Day (June 27, 1999)
>> Response to Rumors About Needles Found... (March 16, 1999)
>> The HIV/AIDS Epidemic in the U.S., 1997-1998 (December 28, 1998)
>> Home Sample Collection Tests for HIV Infection (November 18, 1998)
●What's New:
>> MMWR: HIV/AIDS Among Racial/Ethnic Minority ...(Jan. 14, 2000)
>> Funding: HIV Prevention Projects for CBOs ...(Jan. 13, 2000)
>> Perinatal HIV Prevention Grantees ...(Jan. 10, 2000)
>> Funding: CBA to Improve the Delivery ...(Jan. 7, 2000)
>> Click here to see more of What's New in this site...
●Site Highlights:
>> Frequently Asked Questions
In English
Survey
En Espaol
>> Downloadable Slide Sets
>> HIV/AIDS Satellite Broadcast
>> HIV/AIDS Surveillance Report(Last - October 8, 1999)
>> Index of HIV/AIDS related MMWRs (1981-Present)
>> Kid's Corner
Last Updated: January 14, 2000
Updated By: CDC-NCHSTP-DHAP-TICB
Please send comments/suggestions/requests to: hivmail@cdc.gov
http://www.cdc.gov/nchstp/hiv_aids/sitemap.htm
疫学統計やファクトシート、患者向けパンフレット、診療ガイドラインなど
●Main Topics
★Basic Science
Brochures★パンフレット
Frequently Asked Questions
Slide Sets
★Surveillance
Basic Statistics★統計
HIV/AIDS Surveillance Report
Natl. HIV Serosurv. Summary
Software
★Prevention Research
AIDS Comm. Demo Projects
Project RESPECT
Project RESPECT-2
★Vaccine Research
★Prevention Tools
Fact Sheets★ファクトシート★別掲
★Treatment★
★Funding
★Testing
Rapid HIV Testing
★Evaluation
★Software
APIDS
AnSWR
CDC EZ-Text
HARS
PCATALOG★ソフトカタログ
★Training
●General Information
★Basic Statistics
FAX/Voice Information System
★Brochures★パンフレット
★Conferences★学会
★Fact Sheets★ファクトシート★別掲
★FAQs
★HIV/AIDS FAX System
★HIV/AIDS Information
CDC Natl. Prev. Info. Network
CDC National AIDS Hotline
Traveler's Health
World AIDS Day
★Links to Other Sites
★Media/Campaigns
CDC Press Releases
PSA's Targeting Youth
★Publications★出版物
HIV/AIDS Surveillance Report
HIV/AIDS Related MMWRs
NCHSTP Newsletter★ニユースレター
★Slide Sets
General Epidemiology
AIDS Surveillance - Race/Ethnicity
AIDS Surveillance in Adolescents
AIDS Surveillance in Women
HIV Surveillance
Mortality
Pediatric AIDS Surveillance
Cumulative U.S. AIDS Cases
●CDC Links
About DHAP
NCHSTP Home Page
CDC Home Page
CDC NPIN Home Page
Employment at CDC
●検索可
Brochures
●CDC Publications List - (from the Divisions of HIV/AIDS Prevention)
1999
Intervention Research and Support(March 1999)
Surveillance and Epidemiology(April 1999)
1998
Intervention Research and Support
Surveillance and Epidemiology
1997
Intervention Research and Support
Surveillance and Epidemiology
Compendium of HIV Prevention Interventions with Evidence of Effectiveness(November 1999)★[56p]
Draft Guidelines for National HIV Case Surveillance, Including Monitoring for HIV Infection and Acquired Immunodeficiency Syndrome (AIDS)(December 10, 1998)
●Electronic Sources for HIV/AIDS Information
Fact Sheets
Guide to Microbicide Research and Development(December 1997)
HIV/AIDS Surveillance Report
HIV/AIDS Surveillance Supplemental Report
HIV Counseling and Testing in Publicly Funded Sites, 1995 Summary Report(October 1997) - (PDF format - 1,965,268 bytes / 24 pages)
HIV Counseling and Testing in Publicly Funded Sites, 1996 Annual Report(September 1998)
HIV Counseling, Testing, and Referral Standards & Guidelines(May 1994) - (PDF format - 63,714 bytes / 19 pages)
HIV Health Education and Risk Reduction Guidelines
HIV Occupational Exposure and Management
HIV Partner Counseling and Referral Services(December 30, 1998)
HIV Prevention Among Drug Users: A Resource Book for Community Planners and Program Managers
HIV Prevention Bulletin: Medical Advice for Persons Who Inject Illicit Drugs(May 1997)
(PDF format - 184,455 bytes) or
Plain Text
HIV Prevention Case Management Guidance (September 1997)
HIV Prevention Case Management Literature Review and Current Practice (September 1997)
HIV Prevention Community Planning: For HIV Prevention Cooperative Agreement Recipients (April 7, 1999)
HIV Prevention Community Planning: Shared Decision Making in Action(March 1998) - (PDF format - 377,061 bytes / 21 pages)
HIV Prevention Guidelines (1982-Present)★ガイドライン
MMWR Index (List of MMWRs on HIV/AIDS from 1993)
National HIV Prevalence Surveys, 1997 Summary
Project RESPECT
Project RESPECT-2
Rapid HIV Testing (August 31, 1998)
Suggested Guidelines for Developing an Epidemiologic Profile for HIV Prevention Community Planning(June 1995)
The Northwest Regional Workshop: HIV Prevention Approaches for Alcohol and Drug Use Among Men Who Have Sex With Men (September 1997)(September 1997)
The CDC Business Responds to AIDS and Labor Responds to AIDS Programs (BRTA/LRTA)
●Treatment Guidelines
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents(May 5, 1999)
Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States (January 30, 1998)
Public Health Service Guidelines for the Management of Health-Care Worker Exposures to HIV and Recommendations for Postexposure Prophylaxis(May 15, 1998)
1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus(August 20, 1999)
Workshop on Perinatal HIV Prevention Programs in Developing Country Settings (Added on June 14, 1999)
Last Updated: January 10, 2000
Centers for Disease Control & Prevention
National Center for HIV, STD, and TB Prevention
Divisions of HIV/AIDS Prevention
http://www.cdc.gov/nchstp/hiv_aids/treatment.htm
Antiretroviral Therapy for Potential Nonoccupational Exposures to HIV(January 1998)
CDC HIV/STD/TB Prevention News
Clinical trials
●Current Treatment Guidelines
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents(May 5, 1999)
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection(April 15, 1999)
Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States (January 30, 1998)
Public Health Service Guidelines for the Management of Health-Care Worker Exposures to HIV and Recommendations for Postexposure Prophylaxis(May 15, 1998)
1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus(August 20, 1999)
Drug Interactions
Drug Treatment Information
General Treatment Information
HIV Occupational Exposure and Management
HIV Postexposure Prophylaxis Registry
Neurologic Complications
Recent HIV/AIDS Treatment Advances and the Implications for Prevention
Treatment Information: HIV and Women
Last Updated: December 2, 1999
Centers for Disease Control & Prevention
National Center for HIV, STD, and TB Prevention
Divisions of HIV/AIDS Prevention
Please send comments/suggestions/requests to: hivmail@cdc.gov
http://www.fda.gov/oashi/aids/hiv.html
HIV Infection and AIDS, OSHI Index of FDA related treatment, testing, fraud, prevention, and clinical trials information
Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome
WHAT'S NEW |
HIV AIDS Program Information
●Topic Index
Milestones
HIV/AIDS Therapies
Testing Information
Clinical Trials and Drug Development
Barrier Products
FDA/State AIDS Health Fraud Task Forces,
Evaluating Medical Therapies
News Releases
HIV/AIDS Articles and Brochures
Speeches
Other HIV/AIDS Web Sites
HIV/AIDS Meetings
Comments
last revised January 2,2001.
- HIV, AIDS News and Press Releases, describes FDAs activities relating to HIV and AIDS,OSHI 主に抗エイズ薬情報
[U.S. Food and Drug Administration]
Talk Papers Listed by Calendar Year
1999, | 1998, | 1997, | 1996, | 1995, | 1994, | 1993,
| 1992, | 1991, | 1990, | 1989, | 1988,
| 1987
rainbow line
●2000
Safety Alert on Unapproved Goat Serum Treatment for HIV/AIDS, December 22,2000
, Talk Paper- Potential Safety Concern involving Unapproved Experimental product for HIV/AIDS
●1999
FDA Takes Action Against Firm Marketing Unapproved Drugs (December 10, 1999)
FDA Issues Final Rule on OTC Drug Products Containing Colloidal Silver (August 17, 1999)
FDA Approves First Home Test for Hepatitis C Virus (April 29, 1999)
FDA Approves Agenerase (amprenavir) for HIV Infection (April 16, 1999)
FDA warns about products containing Gamma Buryrolactone or GBL and asks compaines to issue a recall. FDA has received reports of serious health problems - some that are potentially life-threatening-- associated wit the use of these products. (January 21, 1999)
●1998
FDA Approves Abacavir for HIV-1 Infection on December 17, 1998 (December 18, 1998)
FDA Approves Thalidomide for Hansen's Disease, Side Effect Imposes Unprecedented Restrictions on Distribution (July 16, 1998)
FDA Strengthens Warning Label for Propulsid (June 29, 1998)
FDA Approves Alternative to Fresh Frozen Plasma (May 6, 1998)
Important New Safety Information About Hismanal,(February 9, 1998)
●1997［以下略］
Last revised December 13, 1999
News Releases
News Releases, last updated December 20, 1999
Talk Papers, last updated September 27, 1999
News Releases Listed by Calendar Year
1999, 1998, 1997, 1996, 1995,
1994, 1993, 1992,
1991, 1990, 1989,
1988, 1987
●1999
FDA Announces New Internet Website to Provide Consumer with Information About Buying Prescription Drugs and Medical Products Online (Decemebr 20, 1999)
FDA Issues Health Warning About Sun Orchard Fresh Squeezed Unpasteurized Orange Juice, (November 16, 1999)
FDA Announces New Efforts to Help Curb Illigal Prescription Drug Marketing on the Internet (July 30, 1999)
Dietary Supplements Now Labeled with More Information (March 23, 1999)
●1998
FDA Approves New Drug to Treat HIV, AIDS, (September 18, 1998)
FDA Proposes Rules For Dissemination of Information on Off-Label Uses (June 5, 1998)
FDA Issues Draft Guidance on the Promotional Practices of Pharmacy Benefit Companies, (January 5, 1998)
●1997［以下略］
Last revised December 20, 1999
HIV/AIDS Related Meetings
Surgeon General's African American Community HIV/AIDS Satellite Conference, November 30, 1999.
Adefovir (Gilead Sciences, Inc.) new drug application will be discussed
by the FDA Antiviral Drugs Advisory Committee on November 1, 1999.
The meeting will be at the Holiday Inn, Gaithersburg, MD. The complete notice for
the meeting in on the web in Text Format
and PDF format.
FDA Meetings centered around discussion related to HIV viral resistence testing.
Blood Products Advisory Committee (BPAC) meeting on
September 17, 1999 to discuss regulatory classification of drug sensitivity tests.
FDA Discussion with the Community about the
role of HIV resistence testing in new drug development. This meeting will follow the BPAC
meeting on the afternoon of September 17, 1999. Input from this meeting are expected
to contribute to the agenda for the Antiviral Drugs Advisory Committee in November.
Antiviral Drugs Advisory Committee meeting on November 2 and 3, 1999 to discuss the role of HIV resistance testing in new drug development for HIV/AIDS.
Ziagen (abacavir sulfate) Antiviral Drug Advisory Committee Meeting announcement, November 2, 1998
Nitazoxanide (NTZ), Antiviral Drug Advisory Committee Meeting Transcript, May 6, 1998
Satellite Broadcast Series, Adherence to HIV Therapies: HIV Treatment and Prevention Issues, February 24, 1999, 1-3 EST to take a close look at critical issues in disease management. The broadcast will focus on 1) Initiation, maintenance, and improvement of adherence to the new treatment regimens and 2) Role of HIV prevention in the new era of improved HIV disease management.
Executive Summary, Thalidomide: Potential Benefits and Risks, An Open Public Scientific Workshop September 9-10, 1997
Thalidomide: Potential Benefits and Risks, Open Public Scientific Workshop, September 9-10, 1997
FDA Advisory Committee Information Line
Community/Patient Representation on FDA Advisory Committees (updated 5/12/97)
When a Patient Speaks ... Patient Representatives to FDA Advisory Committees
Last revised November 2, 1999
HIV/AIDS Therapeutics
Approved Therapies for HIV/AIDS or AIDS-related Conditions (February 14, 2001)
Antiretroviral HIV Drugs Approved by FDA for HIV Treatment (February 14, 2001)
HIV/AIDS Treatment INDs Allowed to Proceed (updated February 9, 1999)
Antiretroviral HIV Drug Approvals and Pediatric Labeling Information, (April 16, 1999)
The Protease Inhibitors Backgrounder, Updated December 4, 1998, This document profiles the similarities and differences of four approved protease inhibitors, and provides useful information about dosing, storage, potential drug interactions, and therapeutic options. This is an update of the September 1996 backgrounder.
The MedWatch program is to enhance the effectiveness of postmarketing surveillance of medical products as they are used in clinical practice and to rapidly identify significant health hazards associated with these products. Visit the MedWatch page and learn how to work with your health care professional to report possible adverse reactions. The identify of the patient is kept confidential.
MedWatch: FDA's 'Heads Up' on Medical Product Safety , FDA Consumer article discussing the MedWatch program to improve the safety of drugs, biologics, medical devices, dietary supplements, medical foods, infant formulas, and other regulated products by encourageing health care professionals to report serious adverse events and product defects. (November-December 1998)
Norvir, Abbott informs healthcare professionals about manufacturing difficulties with the capsule formulation of their HIV protease inhibitor, Norvir, which will result in a shortage of capsules.
The company has encountered an undesired formation of a Norvir crystalline structure that affects how the capsule form of Norvir dissolves. Their plan is to supply Norvir oral solution (liquid) to provide continued Norvir therapy for patients.
July 28, 1998, Health Professional Letter, Abbott
July 28, 1998, Consumer Letter, Abbott
FDA advises doctors about new warnings of cardiac problems associated with the drug Propulsid (cisapride), a treatment for night time heartburn. This action was prompted by reports of serious adverse reactions -- including heart rhythm disorders and deaths associated mostly with the use of the drug in people who were taking certain other medications, including Protease Inhibitors, or who had particular underlying medical conditions.
Please visit FDA's MedWatch site for Janssen Pharmaceutica "Dear Healthcare Professionals Letter" and FDA Talk Paper
http://www.fda.gov/medwatch/safety/1998/safety98.htm#propul
FDA Public Health Advisory, Reports of Diabetes and Hyperglycemia in Patients Receiving Protease Inhibitors for the Treatment of Human Immunodeficiency Virus (HIV), June 11, 1997
Health Advisory for Newest Class of AIDS Drugs, June 11, 1997
Revised Treatment Guidelines, November 1997,
(1)Guidelines for the Use of Antitretroviral Agents in HIV Infected Adults and Adolescents, "...recommendations, based on the scientific principles, for the clinical use of antiretroviral drugs and laboratory monitoring methods in the treqatment of HIV-infected individuals."
(2) Report of the NIH Panel to Define Principles of Therapy HIV Infection.
Information: Hepatitis "Flares" after Cessation of Lamivudine (Epivir, 3TC) in Patients Chronically Infected with Hepatitis B, September 8, 1997
Dear Doctor Letter - Difficulty in Obtaining Immune Globulin Intravenous (Human)(IGIV),
January 28, 1998 ASCII Format, MS Word Format, PDF Format .
Shortage of Immune Globulin (IVIG) Products, Statement by Lead Deputy Commissioner, FDA May 7, 1998
Last revised November 2, 1999
Approved Drugs for HIV/AIDS or AIDS-related Conditions
July 6, 1999
Abacavir (Ziagen), Glaxo Wellcome
Approved December 17, 1998 to treat HIV-1
in adults and children. Accelerated Approval
Approval Letter
Approved Labeling
●Agenerase (Amprenavir) Glaxo Wellcome
Approved April 15, 1999 to treat HIV-1 in adults and children. Accelerated Approval
Alitretinoin (Panretin) gel 0.1%, Ligand Pharmaceuticals
Approved on February 2, 1999 for the topical treatment of cutaneous lesions in patients
with AIDS-related Kaposi's sarcoma.
Approval Letter Approved Labeling
Amphotericin B Liquid Complex (Abelcet, ABLC, Ambisome), The Liposome
Company
Approved November 20, 1995 for the treatment of aspergillosis
Atovaquone (Mepron, 566C80), Glaxo Wellcome
Approved November 25, 1992 for the
treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients
who are intolerant to Bactrim or Septra.
Approved February 8, 1995 for the treatment of mild to moderate PCP in patients who are
intolerant of Trimethoprim-Sulfamethoxazole (TMP-SMX)
Approved January 5, 1999 for the prevention of PCP. Approval Letter Approved Labeling
Azithromycin (Zithromax), Pfizer, Inc.
Approved June 14, 1996 for the prevention of Mycobacterium avium complex in persons with advanced HIV infection.
Cidofovir (Vistide, HPMPC), Gilead Sciences, Inc.
Approved June 27, 1996 for the treatment of AIDS-related cytomegalovirus retinitis.
Clarithromycin (Biaxin, Klacid), Abbott Laboratories
Approved December 23, 1993 for the treatment of disseminated mycobacterial infections due
to Mycobacterium avium-intracellulare complex (MAC). Accelerated Approval
Approved October 12, 1995 for prophylaxis of disseminated MAC in patients with advanced HIV infection.
Daunorubicin-liposomal (DaunoXome), Nexstar
Approved April 8, 1996 for the treatment of advanced HIV-related Kaposi's sarcoma.
Delavirdine mesylate (DLV, Rescriptor), Pharmacia & Upjohn
Approved April 4, 1997 for use in combination with appropriate antiretrovirals when therapy is warranted for treatment of HIV infection. Accelerated Approval
Didanosine (ddI, Dideoxyinosine, Videx), Bristol Myers-Squibb
Approved October 9, 1991 for treatment of
adult and pediatric patients with advanced HIV who are intolerant to or deteriorating on AZT.
September 1992 expanded indication and dosage recommendations reduced.
Approved July 17, 1996 for treatment of HIV infection when antiretroviral therapy is warranted.
Doxorubicin hydrochloride-liposomal (Doxil), Sequus Pharmaceuticals,Inc.
Approved November 17, 1995 for the treatment of Kaposi's sarcoma in AIDS patients who are intolerant to or have disease progression on prior combination chemotherapy.
Dronabinol (Marinol), Roxane Laboratories
approved December 23, 1992 for the treatment of anorexia associated with weight loss in patients with AIDS.
Efavirenz (Sustiva), DuPont Pharmaceuticals
Approved September 17, 1998 for the
treatment of HIV-1 infection, in combination with other antiretroviral agent(s). New Drug
Application Page
Erythropoietin (EPO, Epogen, Procrit), Amgen
Approved December 31, 1990 for the treatment of anemia related to AZT therapy in HIV infection.
Famciclovir (Famvir), SmithKline Beecham
Approved June 12, 1998 for the treatment of recurrent mucocutaneous herpes simplex infections in HIV-infected patients.
Fluconazole (Diflucan) , Pfizer, Inc.
Approved January 29, 1990 for the treatment of oropharyngeal and esophageal candidiasis
and for the treatment of cryptococcal meningitis.
Approved November 13, 1994 for the treatment of pediatric patients with cryptococcal meningitis and candida infections.
Fomivirsen Sodium Injection ( Vitravene intravitreal injectable), Isis
Pharmaceuticals
Approved on August 26, 1998 for the local treatment of cytomegalovirus (CMV) retinitis in
patients with acquired immunodeficiency syndrome (AIDS) who are intolerant of or have a
contraindication to other treatment(s) for CMV retinitis or who were insufficiently
responsive to previous treatment(s) for CMV retinitis.
Approval Letter, Labeling and Consumer Information
Foscarnet (Foscavir), Astra Pharmaceuticals
Approved September 27, 1991 for the treatment
of cytomegalovirus (CMV) retinitis in patients with AIDS.
Approved June 16, 1995 for the treatment of acyclovir-resistant mucocutaneous herpes
simplex virus infections in immunocompromised patients.
Approved February 1997 for combination therapy with foscavir and ganciclovir of patients who have relapsed after monotherapy with either drug.
Ganciclovir (IV, Oral)(Cytovene, DHPG), Syntex
Approved June 23, 1989 (IV) for treatment of cytomegalovirus (CMV) retinitis in
immunocompromised patients.
Approved December 22, 1994 (oral) for maintenance therapy for CMV retinitis in some
patients.
Approved October 31, 1995 (oral) for prophylaxis of CMV disease.
Ganciclovir (Implant) (Vitrasert), Chiron Corporation
Approved March 5, 1996 for the treatment of cytomegalovirus retinitis in patients with AIDS.
Immune globulin (IV) (Gamimune N, Gamma Globulin, IGIV), Bayer
Pharmaceutical Division
Approved December 27, 1993 for prevention of bacterial infections in pediatric HIV infection.
Indinavir sulfate (Crixivan, IDV, MK-639), Merck & Co.
Approved March 14, 1996 for use alone or
in combination with nucleoside analogues for the treatment of HIV infection in adults.
Accelerated Approval
Approved December 17, 1998 new 333 mg capsule formulation
Interferon Alfa-2a (Roferon-A), Schering-Plough
Approved November 21, 1988 for the treatment of AIDS-related Kaposi's sarcoma in selected patients.
Interferon Alfa2b (Intron-A), Hoffmann-La Roche
Approved November 21, 1988 for the
treatment of adult AIDS-related Kaposi's sarcoma.
Approved February 25, 1991 for the treatment of chronic Non-A, Non-B hepatitis.
Itraconazole (Sporanox), Janssen Pharmaceutical
Approved September 11, 1992 for the treatment of histoplasmosis, blastomycosis, and
aspergillosis in immunocompromized and non-immunocompromised patients.
Approved March 29, 1994 for the treatment of pulmonary and extra pulmonary aspergillosis
in patients who are intolerant of or refractory to amphotericin B.
Approved February 1997 (oral solution) for the treatment of oropharyngeal and esophageal candidiasis..
Lamivudine (Epivir, 3TC), Glaxo Wellcome
Approved November 17, 1995 for combination use with AZT as a treatment option for HIV infection in adults and pediatrics patients greater than or equal to 3 months old. Accelerated Approval
Lamivudine/Zidovudine (Combivir), Glaxo Wellcome
Approved September 27, 1997 for the treatment of HIV infection in adults and adolescents greater than or equal to12 years old.
Megestrol acetate (Megace, Ovarian), Mead Johnson Laboratories
Approved September 10, 1993 for the treatment of anorexia, cachexia, or unexplained, significant weight loss in patients with AIDS.
Nelfinavir mesylate (NFV, Viracept), Agouron Pharmaceuticals
Approved March 14, 1997 for the treatment of HIV infection when antiretroviral therapy is warranted in adults and pediatrics greater than or equal to 2 years old. Accelerated Approval
Nevirapine (Viramune, BI-RG-587), Boehringer Ingelheim Pharmaceuticals,
Inc.
Approved June 24, 1996 for use in combination with nucleoside analogues for the treatment of HIV-infected adults experiencing clinical and/or immunologic deterioration. Accelerated Approval
Paclitaxel (Taxol), Bristol Myers-Squibb Pharmaceutical Research
Institute
Approved August 4, 1997 for the second-line treatment of AIDS-related Kaposi's sarcoma.
Pentamidine (aerosolized) (NebuPent), Fujisawa
Approved June 15, 1989 for the
prevention of Pneumocystis carinii pneumonia.
Rifabutin (Ansamycin, Mycobutin), Adria Laboratories
Approved December 23, 1992 for the prevention of Mycobacterium avium complex in patients with advanced HIV.
Ritonavir (Norvir, ABT-538), Abbott Laboratories
Approved March 1, 1996 for use alone or
in combination with nucleoside analogues for the treatment of HIV infection. Accelerated
Approval
Approved March 14, 1997 for the use of alone or in combination with nucleoside analogues
for the treatment of HIV infection in selected patients.
Approved June 29, 1999 soft gelatin, 100 mg capsule
Saquinavir mesylate ( Fortovase [soft gel capsule], Invirase [hard gel capsule], SQV), Hoffmann-La Roche
Approved December 7, 1995 for combination use with nucleoside analogues for the treatment of advanced HIV infection in selected patients. Accelerated Approval
Somatropin rDNA (Serostim), Serono Laboratories
Approved August 23, 1996 for the treatment of AIDS-wasting and cachexia. Accelerated Approval
Stavudine (d4T, Zerit), Bristol Myers-Squibb
Approved June 17, 1994 for the treatment of
adults with advanced HIV infection who are intolerant to or deteriorating on approved
therapies. Accelerated Approval and Parallel Track
Approved January 4, 1996 for the treatment of adults with HIV infection who have undergone
prolonged treatment with AZT.
Approved September 6, 1996 for the treatment of pediatrics with HIV infection who have undergone prolonged prior AZT therapy.
Sulfamethoxazole/Trimethoprim, Glaxo Wellcome
(Bactrim when combined with Trimethoprim; Septra when combined with Trimethoprim; SMX)
Approved June 23,1981 for the treatment of Pneumocystis carinii pneumonia (PCP)
Approved January 7,1994 for the prevention of PCP.
Trimethoprim/Sulfamethoxazole, Hoffmann La-Roche
(Bactrim when combined with Sulfamethoxazole; Septra when combined with Sulfamethoxazole;
SMX)
Approved June 23, 1981 for the treatment of Pneumocystis carinii pneumonia (PCP)
Approved January 7, 1994 for the prevention of PCP.
Trimetrexate glucuronate (with Leucovorin)(Neutrexin, TMTX), U.S.
Bioscience
Approved December 17, 1993 for the treatment of moderate to severe Pneumocystis carinii pneumonia when intolerant or refractory to TMP/SMX or when TMP/SMX is contraindicated.
Zalcitabine (ddC, Dideoxycytidine, HIVID), Hoffmann-La Roche
Approved June 19, 1992 for combination use
with AZT for the treatment of selected patients with advanced HIV disease. This approval
was based on the accelerated approval regulations.
Approved August 5, 1994 for monotherapy treatment of advanced HIV for those aged more than 13 years who are intolerant to or have disease progression on AZT.
Zidovudine (Azidothymidine, AZT, Retrovir, ZDV), Glaxo Wellcome
Approved March 19, 1987 for the
treatment of adult AIDS, or symptomatic HIV and CD4 less than or equal to 200
September 28, 1989 in syrup formulation
January 1990, decreased recommended dosage
February 2,1990 in intravenous dosage form
March 1990 for use in early symptomatic HIV
disease and in asymptomatic HIV infection where there is evidence of impaired immunity.
May 3, 1990 for the treatment of pediatric
HIV infection (ages 3 months to 12 years)
August 8, 1994 for the prevention of perinatal transmission in HIV+ pregnant women between 14 and 34 weeks gestation and for newborns of HIV+ mothers.
Last revised July 6, 1999
Antiretroviral Drugs Approved By FDA for HIV
April 16, 1999
Brand Name Generic Name Firm Name Approval Date
Retrovir Capsules zidovudine, AZT Glaxo Wellcome 19 March 87
Retrovir Syrup zidovudine, AZT Glaxo Wellcome 28 September 89
Retrovir Injection zidovudine, AZT Glaxo Wellcome 02 February 90
Videx didanosine, ddI Bristol Myers-Squibb 09 October 91
Hivid zalcitabine,ddC Hoffmann-La Roche 19 June 92
Zerit stavudine, d4T Bristol Myers-Squibb 24 June 94
Epivir lamivudine, 3TC Glaxo Wellcome 17 November 95
Invirase saquinavir Hoffmann-La Roche 06 December 95
Norvir ritonavir Abbott Laboratories 01 March 96
Crixivan indinavir Merck& Co., Inc. 13 March 96
Viramune nevirapine BoehringerIngelheim 21 June 96
Viracept nelfinavir Agouron Pharmaceuticals 14 March 97
Rescriptor delavirdine Pharmacia& Upjohn 04 April 97
Combivir zidovudine and lamivudine Glaxo Wellcome 26 September 97
Fortovase saquinavir Hoffmann-La Roche 07 November 97
Sustiva efavirenz DuPont Pharmaceuticals 17 September 98
Ziagen abacavir Glaxo Wellcome 17 December 98
Agenerase amprenavir Glaxo Wellcome 15 April 99
Prepared by: Office of Special Health Issues
Food and Drug Administration
Last revised April 16, 1999
January 13, 2000
FDA Issues Public Health Advisory About Safe and Appropriate Use of Influenza Drugs, January 12, 2000 Advisory Letter and Talk Paper.
Buying Medical Products Online, a new FDA website to help you tell if a Website that sells medical products is legitimate, what you should do before you buy medical products online. This site also contains a link to where you can report problem websites.(HHS News Release, December 20, 1999)
Guidance for Industry, In the Manufacture and Clinical Evaluation of In Vitro Tests to Detect Nucleic Acid Sequences of Human Immunodeficiency viruses Types 1 and 2, Center for Biologics Evaluation and Research, December 1999. In recent years, several technical advances have been made in methodologies for direct detection of viral nucleic acid. This document provides guidance on manufacturing and clinical trial design issues pertaining to the validation of tests based on nucleic acid detection either in the presence or absence of an amplification step.
FDA Takes Action Against Firm Marketing Unapproved Drugs, December 10, 1999. One of the products is MGN-3, a rice-bran extract, promoted as a treatment for cancer and HIV. The firm involved is Lane Labs-USA, Allendale, NJ.
FTC Charges Second Internet Marketer with Misrepresenting Accuracy of HIV Tests, December 1, 1999.
At the request of the Federal Trade Comission, a federal District Court in Orlando, FL, has issued a temporary restraining order against David M. Rothbart, who does business as Medimax, Inc., stopping him from engaging in the marketing and sale of HIV tests and freezing his assets.
Videx (didanosine, ddI), Bristol-Myers Squibb notifies health professionals of a revised warning about fatal and non-fatal pancreatitis in the labeling for Videx, November 19, 1999
Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients, Kimberly Struble, Pharm. D., Division of Antiviral Drug Products, FDA and Stephen C. Piscitelli, Pharm. D. National Institutes of Health, American Journal of Health-System Pharmacists, Vol 56 November 15, 1999
FDA Warning Letters for Unapproved HIV/AIDS Test Kits, November 22, 1999
FTC and FDA Warn Consumers About Ineffective and Unapproved HIV Test Kits; Announce Joint Law Enforcement Actions, November 17, 1999
FDA Issues Health Warning About Sun Orchard Fresh Squeezed Unpasteurized Orange Juice, November 16, 1999
FDA approved, on Thursday, October 28, 1999 a new 200 mg strength of Videx
indicated for once-daily dosing. Videx (didanosine, ddI), is a nucleoside reverse transcriptase inhibitor (nucleoside analog) that is prescribed in combination with other antiretroviral drugs for the treatment of HIV infection. Along with the supplemental approval for the done-daily dose of Videx, the already existing product labeling describing possible clinical complications related to pancreatitis is being strengthened. The manufacturer of the drug, Bristol-Myers Squibb, of Princeton, New Jersey, will be sending detailed safety information about the use of Videx to health care professionals prescribing drugs for treating HIV within the next two weeks. This information will help guide care providers to most safely prescribe the drug and monitor patients.
Adefovir (Gilead Sciences, Inc.) new drug application will be discussed
by the FDA Antiviral Drugs Advisory Committee on November 1, 1999.
The meeting will be at the Holiday Inn, Gaithersburg, MD. The complete notice for the meeting in on the web in Text Format and PDF format.
FDA issues a letter to all IND-holders of antiretrovirals in the development for HIV. The purpose is to encourage sponsors to study their drug in patient populations with limited treatment options, and to collaborate with other drug sponsors to develop therapeutic options. The letter clarifies the agency's position on combining investigational drugs in clinical trials, and designing trials that include treatment experienced populations. This letter was drafted in response to discussions held with respresentatives of several community groups, at the "Salvage Workshop" in Toronto, Canada, in May 1999
FDA Meetings centered around discussion related to HIV viral resistence testing.
Blood Products Advisory Committee (BPAC) meeting on
September 17, 1999 to discuss regulatory classification of drug sensitivity tests.
FDA Discussion with the Community about the role of HIV resistence testing in new drug development. This meeting will follow the BPAC meeting on the afternoon of September 17, 1999. Input from this meeting are expected to contribute to the agenda for the Antiviral Drugs Advisory Committee in November.
Antiviral Drugs Advisory Committee meeting on November 2 and 3, 1999 to discuss the role of HIV resistance testing in new drug development for HIV/AIDS.
EZ MedTest (HIV rapid home-use test kit) In a joint investigation conducted by FDA and the Federal Trade Commission, an unapproved HIV rapid home-use test kit promoted on the Internet and sold domestically was tested by FDA and, in some cases, gave false negative results. FDA is notifying consumers who purchased the "EZ MedTest" marketed by Cyberlinx Marketing, Inc. on the Internet that the test results given by the test are unreliable. Kit purchasers are advised to consult with a health professional regarding other available FDA approved tests that detect antibodies to HIV. The "EZ MedTest" website has been removed from the Internet by Cyberlinx Marketing, Inc. and the firm has voluntarily turned over all remaining test kits to FDA's Office of Criminal Investigations. [July 9, 1999 (Letter- FDA]
MedWatch: FDA's 'Heads Up' on Medical Product Safety , FDA Consumer article discussing the MedWatch program to improve the safety of drugs, biologics, medical devices, dietary supplements, medical foods, infant formulas, and other regulated products by encouraging health care professionals to report serious adverse events and product defects. (November-December 1998)
Updated January 13, 2000
[U.S. Food and Drug Administration]
HIV/AIDS Milestones 1995-1999
●1995 | 1996 | 1997 | 1998
| 1999
1995
On February 8, FDA approved Mepron (atovaquone) for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX).
On February 23, FDA revised the guidance for Home Specimen Collection Kit Systems Intended for Human Immunodeficiency Virus (HIV-1 and/or HIV-2) Antibody Testing.
On March 24, FDA cleared for marketing the first blood test to measure latex antibodies in the blood. The test can be used to help identify people who are allergic to latex and as such assist people in the use of barrier products to prevent HIV transmission.
On April 14, FDA approved Chartex International plc. London, U.K. premarket approval application for the Femidom Female Condom. The product is an intravaginal barrier device and is indicated for use to help prevent pregnancy, which will be used as an indicator of the device's performance in preventing STDs.
In June 1995, FDA published "An FDA Guide To Choosing Medical Treatments," FDA Consumer.
In June 1995, FDA allowed the initiation of an open label study for saquinavir for the treatment of HIV infection and AIDS. Saquinavir, manufactured by Hoffmann-La Roche, is the first protease inhibitor made available outside of ongoing clinical trials.
On June 6, FDA revised the blood donor criteria to exclude prisoners from donating blood, blood components and plasma for 12 months from the last date of incarceration.
On June 16, FDA approved Foscavir (foscarnet) for the treatment of acyclovir-resistant herpes simplex virus.
August 1995, FDA recommended that blood establishments should implement donor screening for HIV-1 antigen using licensed test kits. Although, currently there are no tests for HIV-1 antigen(s) approved for donor screening, FDA issued the recommendation on HIV-1 in advance of the availability of such test in order to provide blood and plasma establishments with maximum time to prepare for this testing.
On September 1, FDA authorized pre-approval distribution of intravenous cidofovir (Vistide) under a treatment IND protocol for HIV-infected persons relapsing cytomegalovirus (CMV) retinitis that has progressed despite treatment.
On September 8, FDA published in the Federal Register a proposed rule to amend its regulations pertaining to investigational new drug applications (INDs) and new drug applications (NDAs). The proposed rule is responsive to one of the recommendations made by the National Task Force on AIDS Drug Development. The proposed rule would clearly define in the NDA format and content requirements the need to present effectiveness and safety data for important demographic subgroups, specifically gender, age, and racial subgroups.
On October 12, FDA approved Biaxin (clarithromycin) for the prevention of Mycobacterium avium complex (MAC).
On October 27, FDA granted marketing approval for Cytovene capsules (oral ganciclovir) as a prophylactic treatment for the prevention of HIV-related cytomegalovirus (CMV) disease.
On November 17, FDA approved Doxil (doxorubicin HCL liposome injection) for the treatment of Kaposi's Sarcoma.
On November 20, FDA granted accelerated approval for Epivir (lamivudine, 3TC) for use in combination with Retrovir (zidovudine, AZT) in treating AIDS and HIV infection.
On November 20, FDA approved Abelcet (amphotericin B lipid complex) for the treatment of aspergillosis.
On December 6, FDA approved Invirase (saquinavir) the first protease inhibitor, for use in combination with other nucleoside analogue medications. This application received approval only 97 days after FDA received the application for marketing.
On December 12, FDA released a report, "Timely Access to New Drugs in the 1990s"An International Comparison," which documents FDA's tough standards do not delay consumer access to important new drugs, compared to other countries and that the United States has available valuable drugs as soon as, and in many cases sooner than, its counterparts around the world. The average U.S. approval time for antiretroviral agents was approximately six months.
On December 21, FDA granted traditional approval for Zerit (stavudine, d4T) for the treatment of HIV infected adults who have received prolonged prior AZT therapy. Zerit had previously been approved under the accelerated approval regulations.
●1996
On March 1, FDA granted full approval for Norvir (ritonavir) for use alone or in combination with nucleoside analogue medications in people with advanced HIV disease. Norvir also received accelerated approval for less advanced HIV disease.
On March 4, FDA granted full approval for Vitrasert (intravitreal implant with Cytovene (ganciclovir) for the treatment of CMV Retinitis.
On March 13, FDA granted accelerated approval for Crixivan (indinavir) for use alone or in combination with nucleoside analogue medications in people with HIV or AIDS. FDA approved the drug in just 42 days after receiving its application for marketing.
On March 14, FDA approved the first antigen test kit, Coulter HIV-1 p24 Antigen Assay, to screen blood donors for HIV-1. It has been estimated that HIV-1 antigen screening could prevent approximately 5-10 cases per year or up to 25 percent of current cases of HIV infection transmitted by transfusion.
On April 8, FDA granted full approval for DaunoXome (daunorubicin citrate lipsome injection) for first line cytotoxic treatment of advanced, HIV-associated Kaposi's Sarcoma
On May 14, FDA approved the first HIV test system that can be used at home and can be purchased over-the-counter (OTC). The
Confide HIV Testing System, developed by Direct Access Diagnostics, is comprised of three integrated components: an OTC home blood collection kit, HIV-antibody testing at a certified lab, and a test result center that provides test results, counseling and referral anonymously.
On June 3, FDA approved Amplicor HIV-1 Monitor Test, an in vitro nucleic acid amplification test for the quantitation of HIV-1 RNA in human plasma. The test is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of disease prognosis.
On June 3, FDA approved the HIV-1 western blot confirmatory test for OraSure's oral collection system. The oral collection system was originally approved in 1994 using an enzyme-linked immunosorbent assay (ELISA)method.
On June 12, FDA approved Zithromax (azithromycin) for preventing or delaying the onset of infection with mycobacterium avium complex (MAC).
On June 21, FDA granted accelerated approval for Viramune (nevirapine) for use in combination with nucleoside analogues to treat adults with HIV infection who have experienced clinical and/or immunological deterioration.
On June, 26, FDA approved Vistide (cidofovir) as an intravenous treatment for AIDS-related CMV retinitis, a potentially severe eye infection that can lead to blindness.
On July 17, FDA issues a letter to health care providers regarding approximately 15 case reports of spontaneous bleeding episodes in HIV positive patients with hemophilia who were being treated with HIV protease inhibitors at the time of the event.
On August 6, FDA approved the first HIV test which uses urine samples. The urine-based test detects the presence of antibodies to HIV-1 using an enzyme-linked immunosorbent assay (ELISA) method.
On August 23, FDA approved Serostim (somatropin rDNA origin for injection) for treatment of AIDS wasting and cachexia.
●1997
On February 21, FDA approved a supplemental indication for Sporanox (itraconazole) for the treatment of oropharyngeal and esoplogeal candidiasis.
On March 14, FDA granted accelerated approval for Viracept (nelfinavir) the first protease inhibitor labeled for use in children, as well as adults.
On March 14, FDA approved pediatric labeling for the protease inhibitor Norvir (ritonavir).
On April 4, FDA granted accelerated approval for Resciptor (delavirdine), a non-nucleoside reverse transcriptase inhibitor (NNRTI), for use in combination with other antiretroviral drugs for the treatment of HIV-1.
On June 11, FDA issued a Public Health Advisory regarding reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of HIV-1.
On August 4, FDA approved Taxol (paclitaxel) for second line treatment of AIDS-related Karposi's Sarcoma.
On September 17, FDA approved Famvir (famciclovir) for the suppression of recurrent episodes of genital herpes in immunocompetent adults.
On September 26, FDA approved Combivir, a combined form of AZT and 3TC, two previously approved antiretroviral drugs for the treatment of HIV-1.
On September 26, FDA warns consumers and pharmacists about two unapproved, fraudulently marketed home-use test kits which were advertised on the Internet for home HIV and Hepatitis A testing.
On September 26, FDA issued a final rule requiring labeling of latex condoms to contain an expiration date based upon physical and mechanical testing performed after exposing the product to varying conditions that age latex.
On November 7, FDA approved Fortovase, a new formulation of Invirase (saquinavir) for the treatment of HIV-1.
●1998
On January 8, 1998, FDA approved Glyde Dam Lollyes (Glyde USA, Inc., Redmond, WA 98052-4712) designed as a barrier for use while performing cunnilingus. When properly used, it may help reduce the risk of catching or spreading many Sexually Transmitted Diseases (STDs) such as syphilis, gonorrhea, chlamydia infections, gential herpes and HIV; however, it cannot eliminate the risk.
On February 27, FDA cosponsored a 2 hour satellite broadcast from its television studio discussing the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents.
On May 6, 1998, FDA approved a virally inactivated, processed blood product (SD Plasma) manufactured from pooled human plasma that can serve as an alternative to fresh frozen plasma. The manufacturing process for this new product includes a solvent detergent procedure that inactivates some blood-borne viruses such as HIV.
On May 28, 1998, FDA approved Cambridge Biotech HIV-1, a Human Immunodeficiency virus Type 1 (Western Blot) test with a new indication for urine specimen testing.
On June 12, 1998, FDA approved Famvir (famciclovir/SmithKline Beechman) for the additional indication for the treatment of recurrent mucocutaneous herpes simplex infections in HIV-infected patients at a dose of 500 mg twice daily.
On July 22, 1998 FDA cosponsored a 2 hour satellite broadcast from its television studios discussing the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.
On July 23, 1998, FDA issues guidance to manufacturers of Latex Condoms for Men -Information for 510(k) Premarket Notifications: Use of Consensus Standards for Abbreviated Submissions ( pdf file)
On August 26, 1998, FDA approved Vitravene Injection (fomivirsen sodium intravitreal injectable), Isis Pharmaceuticals, for the local treatment of cytomegalovirus (CMV) retinitis in patient with acquired immunodeficiency syndrome (AIDS) who are intolerant of or have a contraindication to other treatment(s) for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis. Approval Letter and Labeling.
On September 17, 1998, FDA approved Sustiva (efavirenz), DuPont Pharmaceuticals, to treat HIV and AIDS. Approval Letter |Approved Labeling |Sustiva Consumer Information
Ziagen (abacavir), Glaxo Wellcome, received accelerated approval on December 17, 1998 to treat HIV-1 in adults and children.
●1999
Panretin (alitretinoin) gel 0.1% was approved on February 2, 1999 for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. The manufacturer is Ligand Pharmaceuticals. Approval Letter Approved Labeling
Businessman Sentenced to Over Five Years for Selling Bogus HIV-Testing Kits (February 17, 1999)
Glass Capillary Tubes: Joint Safety Advisory About Potential Risks, February 1999. This document discusses the potential risk of injury and/or infection from bloodborne pathogens, including HIV, hepatitis B and hepatitis C viruses, due to the accidental breakage of glass capillary tubes, and to recommend certain steps that can minimize the risk.
On March 2, 1999, FDA approved a supplement to AMPLICOR HIV-1 MONITOR Test
(Roche Molecular Systems, Inc.). This supplemental approval extends the lower limit of quantitation from 400 HIV RNA copies/mL down to 50 copies/mL; the upper limit of quantitation, 750,000 HIV RNA copies/mL remains the same. It is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. On the same date, another supplement was approved for patient monitoring and it can be used as an aid in management of patients on anti-viral therapy for HIV disease. The original application, approved June 3, 1996, was for disease prognosis in conjunction with clinical presentation and other laboratory markers. (Labeling, 53 pages in PDF)
Ozone Generator Sentencing - On March 29, 1999, Kenneth Thiefault and his wife Mardol Barber were sentenced in a Florida court for their conviction last year on conspiracy, distribution of an ozone generator, mail fraud, wire fraud, and tax violations. The court sentenced Mr. Thiefault to 72 months of incarceration (to be followed by 3 years of supervised release), imposed a $100,000 fine, and ordered payment of $14,400 in restitution. The court sentenced the Ms. Barber to 33 months of incarceration (to be followed by 3 years of supervised release) and imposed a fine of $60,000. Additionally, the court ordered both defendants to help the IRS compute their back taxes and banned both defendants from participating in any securities or telemarketing businesses in the future. The couple were making claims that the ozone generators can oxidize toxins in the body and cure everything from gangrene to cancer to AIDS.
Agenerase (amprenavir, Glaxo Wellcome, Inc.) 50 mg, 150 mg capsules and oral solution received accelerated approval on April 15, 1999. Agenerase is a protease inhibitor that is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV RNA levels and CD4 cell counts in controlled studies of up to 24 weeks in duration. At present, there are no results from controlled trials evaluating long-term suppression of HIV RNA or disease progression with Agenerase.
>Last revised October 7, 1999
Other Useful Web Sites
AIDS Clinical Trials Information Service (ACTIS)
HIV/AIDS Treatment Information Service (ATIS)
Agency for Health Care Policy and Research (AHCPR)
Centers for Disease Control and Prevention (CDC)
CDC Division of HIV/AIDS Prevention (DHAP)
CDC HIV/AIDS, STD, TB, Prevention News Update
CDC Division of STD Prevention (DSTDP)
CDC Hospital Infections Program (HIP)
CDC National AIDS Clearinghouse (CDC NAC)
CDC National AIDS Hotline
CDC National Center for HIV, STD & TB Prevention (NCHSTP)
CDC National Center for Infectious Diseases (NCID)
Department of Health and Human Services (HHS)
Health Resources and Services Administration (HRSA)
HRSA, HIV/AIDS Bureau
Healthfinder
Library of Congress
National Cancer Institute (NCI)
National Center for Health Statistics (NCHS)
National Clearinghouse for Alcohol and Drug Information (NCADI)
National Health Information Center (NHIC)
National Immunization Program (NIP)
National Insitute for Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
NIH, Office of AIDS Research
NIH, Office of Dietary Supplements
NIH, Office of Research on Women's Health
NIH, National Eye Institute
NIH, Human Subject Protections, OHSR
NIH, National Center for Complementary and Alternative Medicine
National Institute for Mental Health (NIMH)
National Library of Medicine (NLM)
Medline Plus, National Library of Medicine
National Women's Health Information Center (NWHIC)
Office of Minority Health Resource Center (OMHRC)
Substance Abuse and Mental Health Services Administration (SAMHSA)
U.S. Census Bureau
U.S. Government Printing Office (GPO)
Govbot, Database of Government Web Sites
Last Revised November 5, 1999
What's New? | Treatment Information★治療情報 | Treatment Guidelines★診療ガイドライン
Net Links | Contact Us | ATIS Home
●FDA Approved Drugs
Panretin for patients with AIDS-related Kaposi's sarcoma (KS)
Antiretroviral Agents for the Treatment of HIV Infection
Antiretroviral Drugs Approved By FDA for HIV
FDA Approved Drugs for HIV Infection and AIDS-Related Conditions
Antiretroviral HIV Drug Approvals and Pediatric Labeling Information
●Brochures/Publications:
Attacking AIDS with a 'Cocktail' Therapy - FDA Consumer Magazine
HIV Protease Inhibitors & You
Understanding Viral Load
FDA Protease Inhibitors Backgrounder - updated periodically by the FDA
Bibliography: Protease Inhibitors and Viral Load, 1996
Making It Easier to Read Prescriptions
Why Should FDA Regulate Drugs? - An Interview with Janet Woodcock, M.D., Director of FDA's Center for Drug Evaluation and Research
Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society-USA Panel
●Press Releases:
1999
July 16, 1999: Fusion-competent Vaccine: An Immunogen that Induces
a Potent, Broadly Reactive Anti-HIV Neutralizing Response in Mice
- NIAID
July 13, 1999: Combination HIV Vaccine Induces Diverse Immune Responses
- NIH
June 21, 1999: Scientists Suggest New Approaches for Development
of AIDS Drugs and Vaccines - NIH News Release
May 26, 1999: New Anti-HIV Therapies Needed To Eradicate HIV -NIH News Release
April 16, 1999: FDA Approves Amprenavir for HIV Infection -- FDA Talk Paper
March 11, 1999: Dr. Gary Nabel Named Director of NIH Vaccine
Research Center - NIH News Release
December 1998
December 18, 1998:
FDA Approves Abacavir for HIV Infection -- FDA Talk Paper
December 16, 1998:
Study Offers Hope for Immune Reconstitution After HIV Infection --NIH News Release
December 9, 1998:
FDA Approves Hepatitis C Combination Product for Use in Previously
Untreated Patients -- FDA Talk Paper
December 2, 1998:
Fogarty International Center Announces Funding of AIDS International
Training and Research Program Grants -- NIH News Release
November 1998
November 15, 1998:
Treatment with IL-2 Plus HAART Markedly Reduces HIV in Immune System
"Hiding Places" -- NIH News Release
October 1998
October 28, 1998:
Study Finds Less Intensive Treatments May Not Maintain HIV Suppression-- NIH News Release
October 23, 1998:
Fresh Citrus Juice Manufacturers Can Ask For Extra Time -- FDA Talk Paper
October 8, 1998: Scientists Report New Lead in the Regulation of HIV
Coreceptor -- NIH News Release
February 1998
February 18, 1998: Short-Course Regimen of AZT Proven Effective in
Reducing Perinatal HIV Transmission: Offers Hope for Reducing Mother-to-Child
HIV Transmission in Developing World -- HHS
February 2, 1998: Fauci: New Findings Help Explain "Rebound" of HIV
in Patients Who Discontinue Triple-Drug Therapy - Data Suggest Strategies
to Purge Latently Infected Cells -- NIAID
January 15, 1998: 3-D Structure of HIV Components May Pave the Way
for New Anti-AIDS Drugs -- NIH
1997 press releases
1995-1996 press releases
Last updated on January 7, 2000
General Treatment
General information on HIV/AIDS treatment
Drug Treatment
Protease inhibitors, approved drugs, viral load, and more
HIV & Women
Treatment information for women, including during pregnancy
Other Resources
Special Topics, including HIV and hepatitis C co-infection, nutrition and food safety, and the ATIS publications list
Last updated on June 24, 1999
=======================================================
■Treatment Information●AIDS Treatment Information Service (ATIS): Drug Information
●FDA Approved Drugs●FDA承認品目
Panretin for patients with AIDS-related Kaposi's sarcoma (KS)
Antiretroviral Agents for the Treatment of HIV Infection★ＨＩＶ感染治療ガイド
Antiretroviral Drugs Approved By FDA for HIV★抗エイズ薬ＦＤＡ承認品目一覧
| FDA Approved Drugs for HIV Infection and AIDS-Related Conditions
| Antiretroviral HIV Drug Approvals and Pediatric Labeling Information
●Brochures/Publications:●パンフ類
| HIV Protease Inhibitors & You
Spanish version available: Los Inhibidores de la Proteasa del VIH y Usted
| Understanding Viral Load
FDA Protease Inhibitors Backgrounder - updated periodically by the FDA
Bibliography: Protease Inhibitors and Viral Load, 1996
Making It Easier to Read Prescriptions
Why Should FDA Regulate Drugs? - An Interview with Janet Woodcock, M.D., Director of FDA's Center for Drug Evaluation and Research
Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society-USA Panel
●Press Releases:1999
April 16, 1999: FDA Approves Amprenavir for HIV Infection -- FDA Talk Paper
March 11, 1999: Dr. Gary Nabel Named Director of NIH Vaccine Research Center -NIH News Release
★December 1998
December 18, 1998: FDA Approves Abacavir for HIV Infection -- FDA Talk Paper
December 16, 1998:
Study Offers Hope for Immune Reconstitution After HIV Infection --
●NIH News Release
December 9, 1998: FDA Approves Hepatitis C Combination Product for Use in Previously Untreated Patients -- FDA Talk Paper
December 2, 1998:
Fogarty International Center Announces Funding of AIDS International
●Training and Research Program Grants -- NIH News Release
November 1998
November 15, 1998:
Treatment with IL-2 Plus HAART Markedly Reduces HIV in Immune System
"Hiding Places" -- NIH News Release
★October 1998
October 28, 1998:
Study Finds Less Intensive Treatments May Not Maintain HIV Suppression
-- NIH News Release
October 23, 1998: Fresh Citrus Juice Manufacturers Can Ask For Extra Time -- FDA Talk Paper
October 8, 1998: Scientists Report New Lead in the Regulation of HIV Coreceptor -- NIH News Release
★February 1998
February 18, 1998: Short-Course Regimen of AZT Proven Effective in
Reducing Perinatal HIV Transmission: Offers Hope for Reducing Mother-to-Child
HIV Transmission in Developing World -- HHS
February 2, 1998: Fauci: New Findings Help Explain "Rebound" of HIV
in Patients Who Discontinue Triple-Drug Therapy - Data Suggest Strategies
to Purge Latently Infected Cells -- NIAID
January 15, 1998: 3-D Structure of HIV Components May Pave the Way
for New Anti-AIDS Drugs -- NIH
1997 press releases
1995-1996 press releases
Last updated on June 24, 1999
=======================================================
Drug Information●antiretroviral agents for the treatment of hiv infection★ＨＩＶ感染治療ガイド
Recommended Antiretroviral Agents for Treatment of Established HIV Infection★抗ＨＩＶ療法推薦ガイド
1. HIV enters a CD4+ T cell.
2.HIV is a retrovirus (its genetic information is stored on single-stranded RNA instead of the double-stranded DNA found in most organisms). In order to replicate, HIV uses an enzyme known as reverse transcriptase to convert its RNA into DNA.
●非核酸系逆転写酵素阻害剤
The Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) stop HIV production by binding directly onto reverse transcriptase and preventing the conversion of RNA to DNA.
The present NNRTIs approved by the Food and Drug Administration for the treatment of HIV are:
nevirapine (Viramune®)
efavirenz (Sustiva™)
delavirdine (Rescriptor®)
These drugs are called "Non-Nucleoside" Reverse Transcriptase Inhibitors because even though they work at the same stage as Nucleoside Reverse Transcriptase Inhibitors, they act in a completely different way.
●核酸系逆転写酵素阻害剤
3. The Nucleoside Reverse Transcriptase Inhibitors (NRTIs) act by incorporating themselves into the DNA of the virus, thereby stopping the building process. The resulting DNA is incomplete and cannot create new virus.
The present NRTIs approved by the Food and Drug Administration for the treatment of HIV are:
abacavir (Ziagen™, 1592U89)
AZT (ZDV, zidovudine, Retrovir®)
3TC (lamivudine, Epivir®)
Combivir (zidovudine/ lamivudine)
ddC (zalcitabine, dideoxycytidine, HIVID®)
d4T (stavudine, Zerit®)
ddI (didanosine, Videx®)
●プロテアーゼ阻害剤
4. Once the HIV DNA enters the nucleus of the CD4+ T cell and inserts itself into the cell's DNA, it instructs the cell to make many copies of the original virus.
Protease Inhibitors (PIs) work at this stage of the virus reproduction cycle. They prevent HIV from being successfully assembled and released from the infected CD4+ T cell.
The present PIs approved by the Food and Drug Administration for the treatment of HIV are:
indinavir (Crixivan®)
ritonavir (Norvir®)
nelfinavir (Viracept®)
saquinavir (Invirase™ and Fortovase™)
Contact telephone numbers for additional information
Library
Adult and Adolescent Guidelines
Pediatric Guidelines
Perinatal Guidelines
Health-Care Worker Exposure Guidelines
Nonoccupational Exposure Considerations
Opportunistic Infections Guidelines
Previous versions of guideline documents are available
in the Archives
● | Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents * + (The Living Document: May 5, 1999)
This is a living document
that reflects the current state of knowledge regarding the use of antiretroviral
agents. However, this is a rapidly evolving field of science and the
Panel will continually review new data as it becomes available and incorporate
changes to the document as appropriate. Changes from the previous document
(December 1998) are highlighted to make it easier to identify
additions and deletions to the document. Future changes will continue to be made to this version.
Need help downloading the Adult Guidelines document?
●
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection * +
(The Living Document: April 15, 1999)
This is a living
document that reflects the current state of knowledge regarding the
use of antiretroviral agents. However, this is a rapidly evolving field
of science and the Working Group will continually review new data as
it becomes available and incorporate changes to the document as appropriate.
Changes from the previous document (March 1999) are highlighted
to make it easier to identify additions and deletions to the document.
Future changes will continue to be made to this version.
●
Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States
* +(MMWR: January 30, 1998)
●
Public
Health Service Guidelines for the Management of Health-Care Worker Exposures
to HIV and Recommendations for Postexposure Prophylaxis(MMWR: May 15, 1998)
Appendix
First-line Drugs for HIV Postexposure Prophylaxis (PEP)
●
Management of Possible Sexual, Injecting-Drug-Use, or Other Nonoccupational Exposure to HIV, Including Considerations Related to Antiretroviral Therapy* +(MMWR: September 25, 1998)
A Public Health Service Statement report that provides background information on patient management options and presents considerations for antiretroviral therapy.
●
DRAFT1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus (Draft: May 14, 1999)* +
The draft 1999 Guidelines represent
an update of guidelines published in 1995 and in 1997. They include
recommendations to prevent major opportunistic infections in the era
of highly active antiretroviral therapy (HAART). Changes made to the guidelines from the 1997 version are bolded.
Request for Hardcopies: Requests for hardcopies of the document can be obtained by contacting the CDC at Division of HIV/AIDS Prevention, Mailstop E-49, Centers for Disease Control and Prevention, Atlanta, GA 30333 or by telephone (404) 639-2072 or FAX (404) 639-2007.
Last updated on June 14, 1999
The AIDS Clinical Trials Information Service (ACTIS) provides quick and easy acc
ess to information on federally and privately funded clinical trials for adults and children.
Visit our sister service for federally approved treatment guidelines:
ATIS: HIV/AIDS Treatment Information Service
ACTIS Site Awards:
CiteLine 'Valuable Resource'World Wide Web Health Award
Combination HIV Vaccine Induces Diverse Immune Responses
Enhanced
"Search the Site" Feature Overview of new site features
We welcome your feedback !
ACTIS is sponsored by:
FDA: Food and Drug Administration
NIAID: National Institute of Allergy and Infectious Diseases
NLM: National Library of Medicine
CDC: Centers for Disease Control and Prevention
---------------
What's New
Databases
Vaccine Info
Education
Other Trial Resources
Bullet
Communicate
Search the Site
Contact ACTIS ALIGN=BOTTOM
Contact Web Administrator
Last updated on July 13, 1999-->
Current View: General Clinical Trials Databases
Change View to Technical Clinical Trials Databases
ACTIS Databases
These databases provide information about new and ongoing clinical
trials that evaluate experimental drug treatments for adults and children
at all stages of HIV/AIDS. Vaccine trials for HIV prevention are included.
AIDSTRIALS Database --Search for federally and privately sponsored clinical trials
AIDSDRUGS Database
--Search for drugs being tested or evaluated in AIDS clinical trials
AIDS Clinical Trial Results Database --Bibliographic references to journal articles presenting the interim or final results of HIV/AIDS-related clinical trials
New and Ongoing Clinical Trials
--Search the AIDSTRIALS Database divided by category: adults, children, and vaccines
Other U.S. Government Clinical Trials Databases
NIH Clinical Center -- Warren Grant Magnuson Clinical Center
PDQ®-- National Cancer Institute's Comprehensive Cancer Database
★AIDS/HIV百科とリソース[５分野22項目の科学解説］、★二ユースThe Daily Update（回10件程度のダイジェスト）、★新聞記事の完全なスクラップブックCity Newspapers［内部online利用可］★主要ニュースレター★AIDS Treatment Data Network（年１回治療レビユー記事５件前後）、AIDS Treatment News（月２回学術ニュース５件程度）、AIDS Weekly Plus（週刊学術ニュース２から３件）、★Drug Fact Sheets (ACTIS)医薬品ファクトシート※薬剤別に新聞記事、ニュースなどからデータクリップ［治験薬含む；大量］など膨大なデータ提供
●トピックス●Key Topics★AIDS/HIV百科とリソース
The Basics★エイズとは？[ﾌｧｸﾄｼｰﾄ含む]
Treatment★治療に関する詳細なデータと解説
Prevention★主に性感染についての一般向け解説
Exposure Issues★感染が疑われた場合の対処法［１１項目］
Living with HIV★以下７項目の患者ガイド
Daily Life| Nutrition| Supplements| Alternative Treatments| Insurance Issues| Discrimination| Unapproved Substances
The Science of HIV★ＨＩＶの科学［５分野22項目の科学解説］
Groups
Women's Issues| Children & Young Adults| Other Groups
●二ユース●News Services
Today's HIV News
The Daily Update★回10件程度のダイジェスト
AIDS Active Desktop
AIDS News Via Email
City Newspapers★以下の新聞記事の完全なスクラップブック［内部online利用可］
Bay Area Reporter
Chicago Tribune
Dallas Morning News
Los Angeles Times
Miami Herald
Miscellaneous News Sources
Newsday
San Francisco Chronicle
San Francisco Examiner
Sunday Times (So. Africa)
Washington Blade
●News Services (HIV-specific)
Daily Update
AIDS Treatment News
AIDS Weekly Plus
FDA News
NIAID News
NIH News
PANOS Institute
●News Services (Mainstream)
BBC (England)
CNN
IRIN (Africa)
PANA (Africa)
Wall Street Journal
●Wire Services (Mainstream)
Agence France Presse
Associated Press
Businesswire
InterPress News
PR Newswire
Reuters NewMedia
UPI
●法務●Law Library
U.S. Supreme Court
Decisions| Briefs
U.S. Appellate Courts
1st Circuit| 2nd Circuit| 3rd Circuit| 4th Circuit| 5th Circuit| 6th Circuit| 7th Circuit| 8th Circuit| 9th Circuit| 10th Circuit| 11th Circuit
District of Columbia
Publications| ADA Handbook| Law Journals| Social Security
●出版物●Publications
Activist★地域団体出版物
Being Alive| GMHC| NOTES| Women Alive
General★主要ニュースレター★
AIDS Treatment Data Network★年１回治療レビユー記事５件前後
AIDS Treatment News★月２回学術ニュース５件程度
AIDS Treatment Update★月刊ニュース５件程度[現在May 1998迄]
AIDS Weekly Plus週刊学術ニュース２から３件
Patient Oriented●一般向け
Being Alive| BETA| CATIE| GMHC
HIVPlus| New Mexico AIDS InfoNet| NOTES| Project Inform
STEP - Seattle| TAG - New York| Women Alive
Professional●専門家向け
AIDS Weekly Plus| Hopkins HIV Report| IAPAC Journal
U.S. Government●政府系機関の出版物
CDC
Daily Update| Emerging Infectious Diseases
Fact Sheets★疫学ファクトシート
Hotline Training Bulletins| Morbidity And Mortality Weekly Report| Surveillance Report| NLM| AIDSLINE
Drug Fact Sheets (ACTIS)★医薬品ファクトシート※薬剤別に新聞記事、ニュースなどからデータクリップ［治験薬含む；大量］
Clinical Trials (ACTIS)
NIAID
Agenda
Fact Sheets★NIAMIDファクトシート
VA
U.S. Groups●
HIV Info Web
Non-U.S. Groups●
IRIN (United Nations)
Migrants Against AIDS
WHO Surveillance Report
Books in Print
●レファレンス●Reference
General
Science
Statistics
History
●Connecting to Others●
Chat & Bulletin Boards
HIV Info Web
New Mexico AIDS InfoNet
Patient Resources (US)
Migrants Against AIDS
Non-US Resources
●●Links★別記[膨大な解説付きリソース集]
●●About AEGIS
Site Map
How AEGIS Started
Link to AEGIS
Mission Statement
Privacy Promise
Awards
Please Help Us!
Preferences
Feedback
HIV: The Basics
=======================================================
■AEGIS■●Publications■出版物
[Activists]
[Treatment]★治療
[U.S. Government]★政府系出版物
[Non-U.S. Groups]
[Books In Print]
=======================================================
■AEGIS Publications●[Treatment]
●General
Treatment Review
AIDS Treatment News
AIDS Treatment Update, United Kingdom
●Patient Oriented
Being Alive Los Angeles
BETA, Bulletin of Experimental Treatments for AIDS
CATIE, Community AIDS Treatment Information Exchange
GMHC, Gay Mens Health Crisis, New York - "Treatment Issues"
HIVPlus, a new quarterly from Out Publishing.
New Mexico AIDS InfoNet Fact Sheets
NOTES, PWA Health Group - "Notes from the Underground"
Project Inform
STEP, Seattle Treatment Education Project
TAG, Treatment Action Group, New York - "TAGline"
Women Alive, Los Angeles.
●Professional
AIDS Weekly Plus
Hopkins AIDS Report, Johns Hopkins University AIDS Service
IAPAC, Journal of the International Association of Physicians in AIDS Care
=======================================================
●Drug Fact Sheets (ACTIS)★医薬品ファクトシート※薬剤別に新聞記事、ニュースなどからデータクリップ［治験薬含む；大量］順序?
June 1999
BMS-232632 [FDA 302A]
Peldesine [USPD 1998]
Being tested in AIDS studies that involve suppressing T cells to stop viral growth. This is a radically different approach to treating HIV infection. Peldesine (BCX-34) is expected to reduce the speed with which the virus develops resistance. The drug's action is highly reversible. T-cell counts return to pretreatment levels within two weeks after the drug is discontinued. [AIDS Alert 1997 Jul;12(7); BUSINESS WIRE / HealthWire April 30 1997]
L-756423 [FDA 300A]
Bromodeoxyuridine [CHEMID]
Marker for incorporation into cellular DNA to measure lymphocyte kinetics[NIAID 97-I-0189]
(+)- Calanolide A [FDA 297A]
(+)-Calanolide A is a novel non-nucleoside reverse transcriptase inhibitor with potent in vitro activity against HIV-1 and unique pharmacokinetic properties. [5th Conf Retrovir Oppor Infect 1998 Feb 1-5]
SU5416 [FDA Note to Correspondents/AIDS Update]
The safety and efficacy of SU5416 in patients with Kaposi's sarcoma, who have failed currently available therapy, is being investigated in phase I/II clinical trials. [SUGEN Press Release, May 15, 1998]
T-20 [FDA295A]
ALVAC(2)120(B,MN)GNP(vCP1452) [Pasteur Merieux Connaught]
ALVAC(1)120(B,MN)GNP (vCP1433) [Pasteur Merieux Connaught]
MKC-442 [Triangle Pharmaceuticals 1998 Investigator's Brochure]
Being tested in Phase II studies against HIV infection[AmFAR Tx Dir 1998;9(2)]
Voriconazole [AmFAR Tx Dir December, 1997]
Being tested for treatment of aspergillosis. [AmFAR Tx Dir December, 1997]
S-1153 [Fuji ImmunoPharmaceuticals Corp]
Targretin [FDA 287A]
Being tested as topical treatment against Kaposi's sarcoma[PR Newswire 05 Jan 96]
GEM 132 [Hybridon]
Under investigation for intravitreal use against ocular CMV infection, and for systemic use against CMV infections in AIDS patients. [PR NewsWire April 7, 1997; PR NewsWire April 7, 1997]
Zintevir [Aronex Pharmaceuticals Inc]
Anti-HIV activity. Currently in clinical phase I trials[Mol Pharmacol 1998 Feb; 53(2)]
AIDSVAX B/E Vaccine [VAX002]
AIDSVAX B/B Vaccine [VAX002]
Vaccine against HIV infection. The FDA has granted permission for Phase III trials of the vaccine. Such are being initiated in the US with the AIDSVAX B/B vaccine, and in Thailand with AIDSVAX B/E, a slightly different version of the vaccine. [Science 1998 Jan 30:279(5351); AP, June 3, 1998]
Interleukin-6 [NIAID ACTG 928]
Human IL-6 is characterized as a glycoprotein consisting of 212 amino acids with numerous post-translational modifications including phosphorylations as well as N- and O-linked glycosylations. [Frontiers Bioscience 1, Dec 1996; In Vivo Veritas Jan 1996]
CPI-1189 [FDA 289A]
SCH 56592 [GMHC Treatment Issue 1996]
ABT-378 [FDA 285A]
PMPA Prodrug [FDA 283A]
Hepatitis A Vaccine (Inactivated) [Physicians Gen RX 1997]
Topotecan [FDA 284A]
Non-Hodgkin's Lymphoma. [AmFAR Tx Dir 1997;8(3)]
HIV p24/MF59 Vaccine [FDA 095]
Terbinafine Hydrochloride [Merck Index 1996]
In clinical trial against fluconazole-resistant candidiasis. [AmFAR Tx Dir 1997;8(3)]
lamivudine/zidovudine tablet [FDA 280A]
Lamivudine/zidovudine reduces HIV RNA and raises CD4 counts relative to control treatments. FDA approved the combination drug on 9/29/97 for the treatment of HIV infection. [AIDS. 1997 Mar 15;11(4):477-83]
Fozivudine tidoxil [USAN 1997]
Rifapentine [USAN 1997]
Prophylactic against Mycobacterium Avium Complex in AIDS patients with CD4 count less than or equal to 75/cubic mm. [USP DI 1997]
L-743,872 [FDA 267A]
In combination with other antifungal agents, being test against Cryptococcus neoformans infections. [Antimicrob Agents Chemother. 1997 Feb;41(2)]
ALRT 1057 [FDA 271A]
Therapy for Kaposi's Sarcoma. [Int Conf AIDS 1996 Jul 7-12;11(1):18]
Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203) [NIAID VEU 028]
Anti-HIV vaccine[Vaccine 1995, Dec; 13(17)]
Erythromycin [USAN 1997]
Erythromycin is used to treat patients with severe anemia that is ascribed to HIV infection or to AZT treatment. [Ann Internal Medicine 1992]
Bupivacaine [Merck Index 1996]
Albendazole [FDA 274A]
Under investigation for treatment of microsporidiosis. [AmFAR Tx Dir 1997;8(3)]
APL 400-047 [VEU 031]
Cyclosporine [ACTG 334]
Study of immune activaton and HIV expression in early HIV disease. [ACTG 334]
Infant Formula [ACTG 247]
Under investigation as a caloric supplementation to improve growth in HIV-infected infants. [NIAID ACTG 247]
Diphenhydramine [NIAID ACTG 350]
PMPA [FDA 269A]
Under investigation for the treatment of primary HIV infections. [FDA 269A]
Valganciclovir [FDA 268A]
Being tested as oral treatment of CMV retinitis[AmFAR Tx Dir December, 1997]
MN rgp 120/HIV-1 [VEU 014C]
Efavirenz [AmFAR Tx Dir December, 1997]
Inhibitor of HIV-1 reverse transcriptase. [AmFAR Tx Dir 1997;8(3)]
Tin Ethyl Etiopurpurin [FDA 261A]
Treatment of Kaposi's sarcoma[Int Conf AIDS. 1996 Jul 7-12;11(2)]
Memantine [USPD 1998]
The cytoprotective effect of memantine in cortical cell cultures may qualify the drug for the treatment of AIDS-related dementia. [Eur J Pharmacol 1993 Aug 10;240(1)]
1263W94 [FDA 263A]
In testing for treatment of cytomegalovirus infection[4th Conf Retro and Opportun Infect. 1997 Jan 22-26]
Influenza virus vaccine [AHFS Drug Information 1997]
Prophylactic to prevent influenza in HIV-infected persons. [AHFS Drug Information 1997]
Nandrolone Decanoate [USAN 1998]
Treatment of hypogonadism associated with megestrol acetate administration in HIV+ women. Used in the management of HIV associated anorexia and weight loss. [AmFAR Tx Dir December, 1997; Annu Conf Australas Soc HIV Med 1997 Nov 13-16;9]
Nelfinavir [USPD 1998]
FDA approved 03/14/97 for the treatment of HIV infection when antiretroviral therapy is warranted in adults and pediatrics >=2 years old. [PDR 1999]
CI-1012 [NIAID 97 I-032]
Under investigation for the treatment of primary HIV infections in asymptomatic HIV-1 infected patients. [NIAID 97 I-032]
LXR015-1 [FDA 258A]
Under investigation for the treatment of primary HIV infections. [FDA 258A]
Testosterone Enanthate [USAN 1997]
Treatment of wasting syndrome. [AmFAR Tx Dir 1996;8(2)]
Interleukin-12 [Incomplete]
Amprenavir [NIAID 94 I-202]
HIV infection. [NIAID 94 I-202]
1592U89 Succinate [AIDS Therapies 1996]
AIDS dementia complex. [FDA 238B]
Measles - Mumps - Rubella Virus Vaccine Live [NIAID ACTG 225]
Measles Virus Vaccine Live [PDR 1997]
Bacteriophage phi X 174 [MeSH]
Hydroxyurea [USAN 1997]
HIV infection. [NIAID ACTG 307]
Cyclodextrin-itraconazole [NCI 96 C-41]
Oropharyngeal candidiasis. [NCI 96 C-41]
Synthetic Peptide Construction 3 [FDA 257A]
HIV infection. [FDA 257A]
SNX-111 [FDA 256A]
Pain related to HIV. [FDA 256A]
Recombinant human nerve growth factor [NIAID ACTG 291]
HIV-related peripheral neuropathy. [NIAID ACTG 291]
Varicella Virus Vaccine Live [Merck & Co June 1996]
Prevention of varicella ( chickenpox ) in HIV-infected patients. [NIAID ACTG 265]
HIV-1 Immunogen [FDA 092]
HIV infection. [FDA 092]
Lodenosine [AmFAR Tx Dir December, 1997]
HIV infection. [NCI 95 C-192]
Levamisole hydrochloride [USAN 1997]
Enhancement of immune function in HIV infection. [Physicians GenRx 1996]
Ritonavir [USPD 1998]
FDA Approved 03/14/97 for use alone or in combination with nucleoside analogues for treatment of HIV infection in pediatrics >=2 years old. Indicated in combination with nucleoside analogs or as monotherapy for the treatment of HIV-infection when therapy is warranted. [Facts and Comparisons 1996; PDR 1999]
ALVAC-HIV MN120TMGNP ( vCP300 ) [NIAID VEU 026]
Prevention of HIV infection. [NIAID VEU 026]
Nitazoxanide [CHEMLINE]
AIDS-related cryptosporidiosis. [FDA 253B]
HBY 097 [FDA 252A]
Primary HIV infection. [FDA 252A]
Heptavalent pneumococcal conjugate vaccine ( 7-valent ) [NIAID ACTG 292]
HIV-associated pneumococcal disease. [NIAID ACTG 292]
Pneumococcal vaccine polyvalent ( 23-valent ) [NIAID ACTG 292]
HIV-associated pneumococcal disease. [NIAID ACTG 292]
A-007 [FDA 247A]
Cutaneous lesions from Kaposi's sarcoma and lymphoproliferative disorders. [FDA 247A]
Selegiline hydrochloride [USAN 1996]
HIV-associated dementia. [FDA 250A]
Thioctic acid [USAN 1997]
HIV-associated dementia. [FDA 250A]
Lobucavir [USAN 1997]
Cytomegalovirus (CMV) infections; HIV infection; Herpes infection. [FDA 248A; AmFAR Tx Dir 1997;8(3)]
ISIS 2922 [Int Conf AIDS 1994 Aug 7-12;10(2)]
FDA approved on August 26, 1998 for the local treatment of cytomegalovirus (CMV) retinitis in patients with AIDS who are intolerant of or have a contraindication to other treatment(s) for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis. [Int Conf AIDS 1994 Aug 7-12;10(2)]
Indinavir sulfate [USPD 1998]
Primary HIV infection. FDA approved 3/14/96 for use alone or in combination with nucleoside analogues for treatment of HIV infection in adults. [Prog Abst Intersci Conf Antimicrob Agents Chemother 1994 Oct; Merck & Co Package Insert 3/96]
P3C541b Lipopeptide [FDA 090]
Primary HIV infection. [FDA 090]
PCLUS [AIDS Therapies 1995 Sep]
Primary HIV infection. [NCI 94 C-159]
ALVAC-HIV MN120TMG ( vCP205 ) [NIAID VEU 022]
Prevention of HIV infection. [NIAID VEU 022]
Interleukin-10 [MeSH]
Enhancement of immune response and inhibition of tumor necrosis factor production in HIV infection. [NIAID 95 I-125]
APL 400-003 [FDA 089]
Primary HIV infection. [FDA 089]
Prednisone [USAN 1997]
HIV-associated nephropathy; HIV-associated idiopathic esophageal ulcer. [Am J Med 1994 Aug;97(2); Am J Gastroenterol 1994 Dec;89(12)]
OPC 14117 [MeSH]
HIV-related cognitive dysfunction. [FDA 242A]
Clavulanate Potassium [USAN 1997]
AIDS-associated sinusitis. [FDA 243A]
HIV-1 C4-V3 Polyvalent Peptide Vaccine [NIAID DATRI 010]
Primary HIV infection. [NIAID DATRI 010]
Mitoguazone dihydrochloride [Merck Index 1996]
Under investigation for the treatment of AIDS-related non-Hodgkin's lymphoma. [AmFAR Tx Dir 1997;8(3)]
HIV p17/p24:Ty-VLP [AIDS 1993 Oct;7(10)]
Prevention of HIV infection. [NIAID VEU 019]
CI-0694 [NIAID 95 I-126]
Possible prevention or reversal of sensitivity to SMX in patients with HIV infection and SMX intolerance. [NIAID 95 I-126]
Magnesium sulfate [USAN 1997]
Alleviation or elimination of hypocalcemia and hypomagnesemia associated with foscarnet infusion. [FDA 020J]
Kynostatin 272 [MeSH]
Primary HIV infection. [Int Conf AIDS 1994 Aug 7-12;10(2)]
Acitretin [USAN 1997]
Treatment of psoriasis in HIV-positive patients. [FDA 239A]
Tecogalan sodium [USAN 1997]
Inhibitor of Kaposi's sarcoma. [AmFAR Tx Dir 1995;7(4)]
SC-52151 [NIAID ACTG 282]
Primary HIV infection. [NIAID ACTG 282]
935U83 [FDA 237A]
Primary HIV infection. Drug development discontinued per company. [FDA 237A; Glaxo Wellcome 4/96]
Sulfadiazine [USAN 1997]
Toxoplasmic encephalitis. [NIAID ACTG 237; AHFS Drug Information 1997]
Isotretinoin [USAN 1997]
Treatment of anal neoplasia secondary to anogenital human papillomavirus infection. [NIAID ACTG 216; AmFAR Tx Dir 1997;8(3)]
Microparticulate Monovalent HIV-1 Peptide Vaccine [NIAID VEU 018]
Prevention of HIV infection. [NIAID VEU 018]
Levocarnitine [USAN 1997]
Zidovudine-induced myopathy resulting from carnitine deficiency. [NINDS 93 N-30]
Vesnarinone [USAN 1997]
Under investigation in the US as a treatment for HIV and Kaposi's sarcoma. [FDA 234A; AmFAR Tx Dir 1997;8(3)]
Adefovir dipivoxil (oral prodrug of PMEA) [NIAID ACTG 310]
Primary HIV infection. [FDA 232A]
FTC [BETA. 1998 Jul;:38]
Antiviral nucleoside analog drug currently in development. Structurally, FTC is similar to 3TC (Lamivudine), but in vitro, it appears to be much more potent against HIV than 3TC. Now in phase II/III clinical trials in HIV-infected patients. [BETA. 1998 Jul;:38; Triangle Pharmaceuticals, Jan. 26, 1999]
Ifosfamide [USAN 1997]
Treatment of AIDS-related non-Hodgkin's lymphoma. [NCI 93 C-207]
TBC-3B Vaccine [NIAID VEU 014]
Prevention of HIV infection. [NIAID VEU 014]
Multivalent HIV-1 Peptide Immunogen [NIAID VEU 017]
Prevention of HIV infection. [NIAID VEU 017]
WF10 [CHEMLINE]
WF10 is an enhancement of immune function in late-stage HIV infection. It is intravenously administered and targets macrophage function. Even HAART (highly active antiretroviral therapy) does not appear effective against the latent HIV surviving in macrophages, a known reservoir of the virus in AIDS patients. [PR Newswire January 7, 1993; Infection 1998 July/August;26(4):201-206]
Diethylhomospermine [AmFAR Tx Dir 1995;7(4)]
Under investigation for refractory AIDS-related diarrhea. [AmFAR Tx Dir 1997;8(3)]
MDL 28574 [CHEMLINE]
Primary HIV infection. [FDA 221A]
Streptomycin sulfate [USAN 1997]
Treatment of HIV-associated multi-drug resistant pulmonary tuberculosis. [NIAID ACTG 238]
Aminosalicylic acid [USAN 1997]
Treatment of multi-drug resistant pulmonary tuberculosis. [NIAID ACTG 238]
Capreomycin sulfate [USAN 1997]
Used as second-line therapy in combination with other antituberculosis drugs for pulmonary tuberculosis. [PDR 1997]
Benztropine mesylate [USAN 1997]
As an active placebo to mimic the side effects of study drugs. [NIAID ACTG 242]
Mexiletine hydrochloride [USAN 1997]
Relief or reduction of pain in HIV-associated peripheral neuropathy. [NIAID ACTG 242]
Ethionamide [USAN 1997]
Used as a second-line agent against tuberculosis in the HIV-infected person. It should be given only with other effective antituberculosis drugs. [NIAID ACTG 238; Drug Evaluations Annual 1995]
Cycloserine [USAN 1997]
Used in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease). When the causative organisms are susceptible to the drug and when treatment with primary medications (streptomycin, isoniazid, rifampin and ethambutol) has proved inadequate. Should be administered with other effective chemotherapy and not as the sole therapeutic agent. [PDR 1997]
Glutamic acid hydrochloride [Facts and Comparisons 1995]
Prevention of hypochlorhydria, in order to enhance absorption of oral ganciclovir. [NIAID ACTG 183]
SC-49483 [NIAID ACTG 259]
Primary HIV infection. [NIAID ACTG 259]
F105 human monoclonal antibody [NIAID ACTG 232]
Inhibition of tumor necrosis factor production in HIV infection. [NIAID ACTG 232]
Anti-Rh antibodies [NCI 93 C-155]
HIV-associated thrombocytopenia. [NCI 93 C-155]
Paclitaxel [USAN 1997]
FDA approved (8/5/97) for the second-line treatment of AIDS-related Kaposi's sarcoma. [MeadJohnson/Bristol-Myers Squibb Package Insert 8/97]
Tumor Necrosis Factor soluble receptor-immunoadhesin complex [NIAID 93-I-206]
Inhibition of tumor necrosis factor production in HIV infection. [AmFAR Tx Dir 1995;7(4)]
Paromomycin sulfate [USAN 1997]
Currently being investigated for treatment of cryptosporidiosis. [AmFAR Tx Dir 1997;8(3); NIAID ACTG 192]
Thymic humoral factor [Facts and Comparisons 1995]
Enhancement of immune response in HIV infection. [AmFAR Tx Dir 1995;7(4)]
Chimeric anti-TNF monoclonal antibody [NIAID 93 I-182]
Inhibition of tumor necrosis factor production in HIV infection. [NIAID 93 I-182]
Doxorubicin hydrochloride (liposomal) [PDR 1997]
Treatment of AIDS related Kaposi's sarcoma. FDA approved 11/17/95 for the treatment of Kaposi's sarcoma in AIDS patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. [PDR 1997; FDA Bulletin]
Thalidomide [USAN 1997]
Currently being studied for possible treatment of mycobacterium infection and wasting syndrome in HIV infection. Successful results have been reported in treatment of various ulcerations including recurrent aphthous stomatitis (RAS). [DICP 1990 Nov; Vol 24 No 11; FDA 133A, FDA 230A; AIDS Therapies 1995 Sep]
Trimetrexate glucuronate [USAN 1997]
For use with concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including those with AIDS, who are intolerant of, or are refractory to, trimethoprim/sulfamethoxazole (TMP-SMX), or for whom TMP-SMX is contraindicated. [PDR 1997]
RMP-7 [AmFAR Tx Dir 1995;7(4)]
Under investigation in combination with amphotericin B in patients with cryptococcal meningitis. [AmFAR Tx Dir 1997;8(3)]
ALVAC-RG rabies glycoprotein ( vCP65 ) [NIAID VEU 012A]
Used as control in vaccine studies. [NIAID VEU 012A]
ALVAC-HIV gp160 MN ( vCP125 ) [NIAID VEU 012A]
Prevention of HIV infection. [NIAID VEU 012A]
882C87 [FDA 130A]
Treatment of localized herpes zoster. [FDA 130A; AmFAR Tx Dir 1995;7(4)]
QS-21 [Ann NY Acad Sci 1995 May 31;754]
Primary HIV infection: as a vaccine adjuvant for the enhancement of the immune response. [NIAID VEU 016; AIDS Res Hum Retroviruses 1995 Feb;11(2)]
Threonyl muramyl dipeptide [CHEMLINE]
Primary HIV infection: as a vaccine adjuvant for the enhancement of the immune response. [NIAID VEU 015]
MF59 [Int Conf AIDS 1993 Jun 6-11;9(1)]
Primary HIV infection: as a vaccine adjuvant for the enhancement of the immune response. Used as an emulsifier system in conjunction with other adjuvants such as MTP-PE. [NIAID VEU 015; J Infect Dis 1994 Nov;170(5); J Infect Dis 1994 Nov;170(5)]
Syntex adjuvant formulation [Vaccine 1993;11(3)]
Primary HIV infection: as a vaccine adjuvant for the enhancement of the immune response. [NIAID VEU 015]
Liposome-encapsulated monophosphoryl lipid A [NIAID VEU 015]
Primary HIV infection: as a vaccine adjuvant for the enhancement of the immune response. [NIAID VEU 015]
Monophosphoryl lipid A [Infect Immu 1990 Mar;58(3)]
Primary HIV infection: as a vaccine adjuvant for the enhancement of the immune response. [NIAID VEU 015]
Aluminum hydroxide [USAN 1997]
Primary HIV infection: as a vaccine adjuvant for the enhancement of the immune response. [NIAID VEU 015]
Lentinan [AmFAR Tx Dir 1993;6(4)]
Enhancement of immune function in HIV infection. [FDA 126A]
Curdlan sulfate [AmFAR Tx Dir 1995;7(4)]
Tested for the treatment of Cytomegalovirus retinitis. [AmFAR Tx Dir 1995;7(4)]
Amitriptyline hydrochloride [USAN 1997]
Relief or reduction of pain caused by HIV-associated peripheral neuropathy. [NIAID CPCRA 022]
Interleukin-4 [AmFAR Tx Dir 1997;8(3)]
AIDS-related Kaposi's sarcoma. [AmFAR Tx Dir 1997;8(3)]
rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine [NIAID VEU 011]
Prophylaxis against HIV infection. [NIAID VEU 011]
Delavirdine mesylate [USPD 1998]
FDA approved 04/04/97 for use in combination with appropriate antiretrovirals when therapy is warranted for treatment of HIV infection. Delavirdine should always be administered with at least one other antiretroviral agent; it should not be used alone in the management of HIV infection. In clinical studies to date it has been used in combination with one or two dideoxynucleoside reverse transcriptase inhibitors such as zidovudine lamivudine or didanosine, for initial management. [AHFS Drug Information 1998]
Thymosin alpha 1 [Bull N Y Acad Med 1989 Jan;65(1)]
Enhancement of CD4 lymphocyte levels in patients being treated for primary HIV infection. [NIAID ACTG 236]
Saquinavir mesylate [USPD 1998]
FDA-approved for use in adults in combination with other antiretrovirals. It was first approved in a hard-gel capsule formulation (Invirase) that was poorly absorbed when given orally. Recently, a soft-gel capsule formulation (Fortovase) with increased bioavailability was approved. [AmFAR Tx Dir 1998;9(2)]
Wobenzym [Oncology 1990;47(6)]
Enhancement of immune function in HIV infection. [FDA 122A]
gp160 Vaccine (Immuno-AG) [NIAID ACTG 205]
HIV infection. [AmFAR Tx Dir 1997;8(3)]
Fluorouracil (Topical) [USAN 1997]
Vaginal application of cream to prevent recurrence of cervical/vaginal dysplasia. [NIAID ACTG 200]
Guaifenesin [USAN 1997]
Prevention of recurrent HIV-associated sinusitis. [NIAID ACTG 186]
Pseudoephedrine hydrochloride [USAN 1997]
Prevention of recurrent HIV-associated sinusitis. [NIAID ACTG 186]
Beclomethasone dipropionate [USAN 1997]
Prevention of recurrent HIV-associated sinusitis. [NIAID ACTG 186]
Cefuroxime Axetil [USAN 1997]
Prevention of recurrent HIV-associated sinusitis. [NIAID ACTG 186]
PMEA [AmFAR Tx Dir 1997;8(3)]
HIV infection. [AmFAR Tx Dir 1997;8(3); Int J Cancer 1995 Mar;61(1)]
Daunorubicin (liposomal) [AmFAR Tx Dir 1997;8(3)]
FDA approved 4/8/96 as first-line therapy for advanced HIV-associated Kaposi's sarcoma. [NeXstar Pharmaceuticals Press Release 4/30/96]
Ro 24-7429 [AmFAR Tx Dir 1993;6(4)]
HIV infection. [AmFAR Tx Dir 1993;6(4)]
rgp120/HIV-1MN [AmFAR Tx Dir 1997;8(3)]
HIV infection. [AmFAR Tx Dir 1997;8(3)]
rgp120/HIV-1IIIB [AmFAR Tx Dir 1995;7(4)]
HIV infection. [AmFAR Tx Dir 1997;8(3)]
SP-303T [FDA 120A]
Treatment of herpes simplex virus lesions. [FDA 120A; AmFAR Tx Dir 1997;8(3)]
Cimetidine [USAN 1997]
Enhancement of immune function in HIV infection. [AmFAR Tx Dir 1995;7(4)]
Saccharomyces boulardii [AmFAR Tx Dir 1997;8(3)]
Under investigation for the treatment of chronic diarrhea in HIV-infected people. [AmFAR Tx Dir 1997;8(3)]
TNP-470 [AmFAR Tx Dir 1995;7(4)]
Under investigation for treatment of Kaposi's sarcoma. [AmFAR Tx Dir 1997;8(3)]
Tretinoin [USAN 1997]
Under investigation for the oral treatment of Kaposi's sarcoma. [AmFAR Tx Dir 1997;8(3); J Clin Oncol 1995 May;13(5)]
Lymphocytes, Activated [NIAID 92 I-248]
Enhancement of immune function in HIV infection. [Blood 1993 Apr 15;81(8)]
Cidofovir [USPD 1998]
Treatment of herpes simplex virus and cytomegalovirus (CMV) retinitis in patients with AIDS. FDA approved 6/27/96 for CMV retinitis. [USP DI 1999; Gilead Sciences Package Insert July 1996; AHFS Drug Information 1999]
Atevirdine mesylate [USAN 1997]
Primary HIV infection. [AmFAR Tx Dir 1995;7(4)]
Sparfloxacin [USAN 1997]
Being investigated for treatment of tuberculosis. Treatment of MAI (Mycobacterium avium-intracellulare) bacteremia in HIV-infected individuals. [Tuber Lung Dis 1992 Dec;73(6); NIAID 92 I-165; AmFAR Tx Dir 1993;6(3)]
Hepatitis B Vaccine (Recombinant) [PDR 1997]
Used as non-HIV viral vaccine control. [NIAID ACTG 205]
Cytomegalovirus Immune Globulin Intravenous (Human) [PDR 1997]
Treatment of HIV-infected patients with CMV viruria. [NIAID 92 I-124]
WR 6026 [AmFAR Tx Dir 1993;6(4)]
Being investigated as prophylaxis or treatment for Pneumocystis carinii pneumonia in HIV-infected patients. [AmFAR Tx Dir 1993;6(4); NIAID ACTG 173]
Nimodipine [USAN 1997]
Under investigation for the treatment of AIDS dementia complex. [AmFAR Tx Dir 1995;7(4)]
Dronabinol [USAN 1997]
FDA approved 12/23/92 for appetite stimulation and the prevention of weight loss in HIV-infected patients. [AmFAR Tx Dir 1995;7(4); USP DI 1997]
Letrazuril [USAN 1997]
Being investigated for the treatment of cryptosporidiosis. Paromomycin and letrazuril should be considered in the treatment of AIDS-related sclerosing cholangitis. [AmFAR Tx Dir 1997;8(3); AIDS. 1993 Nov;7(11)]
Sorivudine [USAN 1997]
Active against HSV-1 and varicella-zoster virus (VZV). [AmFAR Tx Dir 1997;8(3)]
Dacarbazine [USAN 1997]
Treatment of Hodgkin's disease in HIV-infected patients. [AmFAR Tx Dir 1995;7(4); NIAID ACTG 149]
Vinblastine sulfate [USAN 1997]
Treatment of Hodgkin's disease in HIV-infected patients; Kaposi's sarcoma. [Int Conf AIDS 1993 Jun 6-11;9(1)]
Tuberculin Purified Protein Derivative (Mantoux) [PDR 1997]
Diagnostic aid to detect Mycobacterium tuberculosis infections. [AHFS Drug Information 1997]
Somatrem [USAN 1997]
Studied as a treatment for HIV-related wasting and being investigated for its role in the human immune system. [AmFAR Tx Dir 1995;7(4)]
Insulin-Like Growth Factor I [Facts and Comparisons 1995]
Mediates effects of human growth hormone, used to treat HIV-associated wasting. [AmFAR Tx Dir 1995;7(4); J Clin Endocrinol Metab 1994 Feb;78(2)]
Valproic Acid [USAN 1997]
Possible inhibition of the metabolic inactivation of zidovudine (AZT), resulting in a longer duration of AZT effects in the body. [Int Conf AIDS 1992 Jul 19-24;8(3)]
Levofloxacin [USAN 1997]
Primary HIV infection; tuberculosis. [AmFAR Tx Dir 1995;7(4); NIAID DATRI 008; NIAID ACTG 222]
Penicillin G [USAN 1997]
Bactericidal action against penicillin G-susceptible microorganisms. [PDR 1997]
Trichosanthin [Merck Index 1996]
Antiviral treatment. [Facts and Comparisons 1995; Antimicrob Agents Chemother 1994 Feb;38(2)]
Lamivudine [USPD 1998]
Lamivudine has been approved (1995) by the FDA for use in combination with AZT in HIV+ patients under the accelerated approval regulations. Lamivudine has demonstrated antiviral activity in combination with many other antiretrovirals including nucleoside analogs such as stavudine and protease inhibitors. [AmFAR Tx Dir 1998;9(2)]
Pyridoxine hydrochloride [USAN 1997]
Indicated to prevent or treat peripheral neuritis caused by drugs that act as pyridoxine antagonist (eg. isoniazid) and/or increase its excretion in the urine. [Drug Evaluations Annual 1995]
Pyrazinamide [USAN 1997]
An oral antituberculosis drug used in combination regimens. Prophylaxis against Mycobacterium tuberculosis (MTb) in persons dually infected with HIV and MTb. (Used in conjuction with rifampin to help overcome drug resistance.)[NIAID ACTG 177]
Isoniazid [USAN 1997]
An antibiotic which, in combination regimens, is standard for the treatment and prophylaxis of tuberculosis in the HIV infected patient. Administered concurrently with pyridoxine (vitamin B6) to prevent the peripheral neuropathy as well as nearly all other nervous system disorders attributable to isoniazid (INH). [AHFS Drug Information 1997; NIAID ACTG 177]
Interleukin-3 (human, recombinant, E. coli) [AmFAR Tx Dir 1995;7(4)]
Subcutaneous treatment of HIV associated cytopenia. [AmFAR Tx Dir 1995;7(4)]
Polysporin [PDR 1997]
Applied over trifluridine in a clinical study of the effectiveness of trifluridine for HZV infection in AIDS patients (ACTG 172). [NIAID ACTG 172]
Trifluridine (Ophthalmic) [USAN 1997]
Used experimentally for the treatment of acyclovir-resistant and foscarnet-resistant HZV infection. Herpes simplex, mucocutaneous (at nasal, oral, vaginal, and anal openings). [AmFAR Tx Dir 1995;7(4); NIAID ACTG 172]
Valacyclovir hydrochloride [USPD 1998]
Oral valacyclovir is used for the treatment of acute, localized herpes zoster (shingles) and for the treatment of initial episodes of genital herpes infections in immunocompetent adults. Efficacy for the treatment of disseminated herpes zoster in immunocompromised adults has not been established. [AHFS Drug Information 1999]
Alvircept sudotox [USAN 1997]
Primary HIV infection. [AmFAR Tx Dir 1995;7(4)]
Pentoxifylline [USAN 1997]
Under investigation for the treatment of HIV infection and Kaposi's sarcoma. [AmFAR Tx Dir 1997;8(3)]
Nevirapine [USPD 1998]
HIV infection. FDA approved 6/24/96 for use in combination with approved nucleoside analogues for treatment of HIV-infected adults who have experienced clinical and/or immunologic deterioration. [AmFAR Tx Dir 1997;8(3); Boehringer Ingelheim Pharmaceuticals]
Octreotide acetate [USAN 1997]
Under investigation for the treatment of cryptosporidiosis and HIV-related diarrhea. [AmFAR Tx Dir 1997;8(3)]
Ranitidine hydrochloride [USAN 1997]
Enhancement of immune function in HIV infection / enhancement of drug interactions. [Antimicro Agents Chemother 1992 Oct;36(10); AmFAR Tx Dir 1995;7(4)]
Hypericin [AmFAR Tx Dir 1995;7(4)]
HIV infection. [AmFAR Tx Dir 1995;7(4); Am J Hosp Pharm 1994 Feb 15;51(4)]
Amikacin sulfate [USAN 1997]
Under investigation in combination therapy for Mycobacterium avium complex (MAC). [AmFAR Tx Dir December, 1997]
Ethambutol hydrochloride [USAN 1997]
Approved as an anti-mycobacterial antibotic used in combination regimens for tuberculosis. Under investigation in combination therapy for Mycobacterium avium complex (MAC). Should be used in conjunction with at least one other antituberculous drug. Drugs used with ethambutol have included isoniazid, streptomycin, cycloserine, ethionamide, pyrazinamide, viomycin, and aminosalicylic acid. [AmFAR Tx Dir 1997;8(3); NIAID ACTG 135; AHFS Drug Information 1995]
Ciprofloxacin [USAN 1997]
Approved as an oral antibiotic used for treatment of several common bacterial infections; under investigation for combination therapy of Mycobacterium avium infection. [AmFAR Tx Dir 1997;8(3)]
Rifampin [USAN 1997]
Approved as an anti-mycobacterial drug for the treatment of tuberculosis. Under investigation in combination regimens as treatment for Mycobacterium avium infection and prophylaxis for tuberculosis. Frequently used regimens are rifampin and isoniazid; rifampin, isoniazid, and pyrazinamide; rifampin, isoniazid, and ethambutol; and rifampin and ethambutol. [AmFAR Tx Dir 1995;7(4); PDR 1997]
Pentosan polysulfate sodium [USAN 1997]
Primary HIV infection; Kaposi's sarcoma. [NCI 90 C-69; The Extra Pharmacopoeia 1993]
Env 2-3 [AmFAR Tx Dir 1997;8(3)]
Primary HIV infection. [AmFAR Tx Dir 1997;8(3)]
MTP-PE/MF59 [Int Conf AIDS 1992 Jul 19-24;8(2)]
Primary HIV-infection - as a vaccine adjuvant for enhancement of the immune response. [AmFAR Tx Dir 1993;6(4)]
L-697,661 [AmFAR Tx Dir 1993;6(4)]
Primary HIV infection. [AmFAR Tx Dir 1993;6(3)]
Azithromycin [USAN 1997]
FDA approved, 6/12/96, for the prevention of disseminated Mycobacterium avium complex (MAC) disease in persons with advanced HIV infection. [U S Prescribing Information Pfizer Inc]
rgp120/HIV-1 SF-2 [NIAID VEU 015]
Primary HIV infection / prevention. [AmFAR Tx Dir December, 1997]
Mitoxantrone hydrochloride [USAN 1997]
Under investigation for the treatment of Kaposi's sarcoma and lymphoma. [AmFAR Tx Dir 1997;8(3)]
L-697,639 [J Med Chem 1992 Oct 16;35(21)]
Primary HIV infection. [Med Res Rev 1993 May;13(3)]
Acetylcysteine [USAN 1997]
Primary HIV infection. [Pharmacology 1993;46(2)]
Clarithromycin [USAN 1997]
FDA approved 12/23/93 (Biaxin) as a treatment for disseminated mycobacterium avium complex ( MAC ). FDA approved 10/12/95 for the prevention of disseminated Mycobacterium avium Complex ( MAC ) in patients with advanced HIV infection. Under investigation in combination therapy for toxoplasmosis. [Abbott Laboratories Drug Information Packet, Oct 1985; AmFAR Tx Dir 1997;8(3); AHFS Drug Information 1997]
Fialuridine [USAN 1997]
Cytomegalovirus infections. [AmFAR Tx Dir 1993;6(3)]
3'-Deoxy-3'-fluorothymidine [USAN 1997]
HIV infection. [Int Conf AIDS 1992 Jul 19-24;8(2)]
Amphotericin B Lipid Complex [USP DI 1995]
Disseminated fungal infections including cryptococcal meningitis, systemic candidiasis, coccidioidomycosis, and aspergillosis. FDA approved 11/20/95 for patients with aspergillosis who are refractory to or intolerant of conventional amphotericin B. [AmFAR Tx Dir 1995;7(4); FDA Bulletin]
Recombinant p24 Vaccine [Int Conf AIDS 1996 Jul 7-12;11(1)]
Primary HIV infection. [Int Conf AIDS 1996 Jul 7-12;11(1)]
Sevirumab [USAN 1997]
Cytomegalovirus infection. [AmFAR Tx Dir 1993;6(3)]
Polyethylene Glycolated IL-2 [AmFAR Tx Dir 1995;7(4)]
Investigated to determine the effects on the immune system, HIV virus and antibody titers. [J Exp Med 1993 Feb 1;177(2); NIAID ACTG 141]
Cryptosporidium Immune Whey Protein Concentrate (Bovine) [FDA 068A]
Under investigation for the treatment of cryptosporidiosis (cryptosporidium-associated diarrhea). [AmFAR Tx Dir 1995;7(4); FDA 068A]
Chlorhexidine gluconate [USAN 1997]
Oral candidiasis, gingivitis, prevention of thrush. [AmFAR Tx Dir 1995;7(4); AmFAR Tx Dir 1997;8(3)]
Interferon alfa-n3 [USAN 1997]
Condylomata acuminata (genital warts), Kaposi's sarcoma. [USP DI 1995]
Smallpox vaccine [USAN 1997]
Comparative study of HIVAC-1e and the smallpox vaccine in previously vaccinated and unvaccinated volunteers. Control in vaccine studies. [FDA 063A]
Methoxsalen [USAN 1997]
AIDS-Related Complex. [Dermatol Nurs 1993 Feb;5(1)]
Anti-HIV immune serum globulin (Human) [FDA 060A]
Enhancement of immune function in HIV infection. Under investigation for prevention of maternal-fetal HIV transmission. Treatment of pediatric HIV infection. [FDA 060A; NIAID ACTG 185; USP DI 1996]
Filgrastim [USAN 1996]
Used to correct or minimize HIV associated neutropenia and/or drug-induced neutropenia. In AIDS patients receiving zidovudine (ZDV) therapy, filgrastim, either alone or with epoetin alfa, has been used to decrease hematologic toxicity of ZDV. Similarly, filgrastim has been evaluated in hematologic toxicity of ganciclovir, co-trimoxazole, sulfadoxine, and pyrimethamine. FDA approved 2/21/91 for neutropenia due to chemotherapy for cancers including lymphomas and Kaposi's sarcoma. [HHS Press Release, June 27, 1994; AHFS Drug Information 1995]
Rifabutin [USAN 1996]
FDA approved 9/23/92 for prevention of Mycobacterium avium Complex (MAC) bacteremia and disseminated infections in patients with advanced HIV infection. Designated by the FDA as an orphan drug for this use. [AHFS Drug Information 1995]
Atovaquone [USAN 1996]
FDA approved 11/25/92 for the treatment of mild to moderate PCP in patients intolerant to standard therapies. Treatment and suppression of T. gondii encephalitis. Primary prophylaxis of HIV-infected persons at high risk for developing this disease. Limited studies suggest that atovaquone may also be effective in the treatment of ocular and cerebral toxoplasmosis in AIDS patients. [FDA Talk Paper; USP DI 1995; Drug Evaluations Annual 1994]
Liposyn II [J of Parenteral and Enteral Nutrition 1992;16(2)]
Nutritional support. [FDA 041A; FDA 041B; AHFS Drug Information 1997]
Liposyn III [Abbott Laboratories Drug Information Packet, Oct 1985]
Nutritional support. [FDA 041A; FDA 041B]
Etoposide [USAN 1996]
Kaposi's sarcoma. [AHFS Drug Information 1995]
Dinitrochlorobenzene [MeSH]
Local treatment for cutaneous Kaposi's angiosarcoma; stimulation of immune system. [Int Conf AIDS 1992 Jul 19-24;8(3); Int Conf AIDS 1992 Jul 19-24;8(2)]
Diclazuril [USAN 1997]
Successfully used to treat isospora and cryptosporidium infection in HIV patients. [Int Conf AIDS 1991 Jun 16-21;7(2)]
SCH 39304 [CHEMLINE]
Cryptococcal meningitis, oropharyngeal candidiasis. [Antimicrob Agents Chemother 1992 Dec;36(12); NIAID ACTG 125]
Fiacitabine [USAN 1997]
Treatment of cytomegalovirus infections. Phase I studies of fiacitabine have been discontinued due to gastrointestinal toxicity and severe fatigue. [AmFAR Tx Dir 1993;6(3); NIAID ACTG 122]
CD4-IgG [Int Conf AIDS 1992 Jul 19-24;8(2)]
Being developed as an immunoprophylactic agent to reduce the probability of infection following HIV-1 exposure, in settings such as occupational or perinatal exposure to the virus. [AIDS Res Hum Retroviruses]
Amoxicillin [USAN 1997]
Bacterial infections. [FDA 019A]
Ampicillin [USAN 1997]
Treatment of bacterial infections. [FDA 019A]
Ketoconazole [USAN 1997]
Approved oral or topical antifungal drug used for the treatment of systemic or topical fungal infections including candidiasis, candiduria, blastomycosis, coccidioidomycosis, and histoplasmosis. [AmFAR Tx Dir 1997;8(3)]
Clotrimazole [USAN 1997]
Treatment and prophylaxis of oropharyngeal candidiasis and treatment of vulvovaginal candidiasis. [USP DI 1997]
Ceftriaxone sodium [USAN 1997]
An antibiotic under investigation as an alternative to penicillin for the treatment of neurosyphilis. Single dose chancroid therapy may be less effective in HIV patients and other anti-infectives should be used. [AmFAR Tx Dir 1995;7(4); AHFS Drug Information 1997]
Keyhole-Limpet Hemocyanin [Merck Index 1996]
Used as control agent in immune response studies of AIDS patients. [NIAID 87 I-114]
Ibuprofen [USAN 1997]
Inflammation and pain. [Int Conf AIDS 1992 Jul 19-24;8(3)]
Disulfirm [USAN 1997]
Primary HIV infection. [Int Conf AIDS 1989 Jun 4-9;5]
Clofazimine [USAN 1997]
Clofazamine has been used in combination with other antimycobacterial drugs in immunocompromised patients with Mycobacterium avium complex infections. Results have been ineffective, bacteriologic cures are unusual and prognosis is poor. [AHFS Drug Information 1997]
Ditiocarb sodium [USAN 1997]
Enhancement of immune function in HIV infection in patients with ARC or AIDS. Latest findings show no beneficial immunomodulatory effects when patients are treated with ditiocarb sodium. [AmFAR Tx Dir 1993;6(3)]
Thymopentin [USAN 1997]
Stimulation of immune function in HIV patients. [AmFAR Tx Dir 1997;8(3)]
Nystatin [USAN 1997]
Treatment of HIV-related candidiasis. [AmFAR Tx Dir 1997;8(3)]
Megestrol acetate [USAN 1997]
FDA approved 9/10/93 for treatment of anorexia, cachexia, and unexplained substantial weight loss in patients with AIDS. Designated an orphan drug by the FDA for this use. [AHFS Drug Information 1997]
Erythropoietin [Merck Index 1996]
Approved for the treatment of anemia in both AZT-treated HIV-infected subjects and chronic renal-failure patients. It is only indicated in patients with endogenous erythropoietin levels less than 500 mU/ml. [AmFAR Tx Dir 1996;8(2)]
Spiramycin [USAN 1997]
Treatment of chronic diarrhea due to cryptosporidium in patients with HIV infection. Per 4/2/93 communication - spiramycin is not helpful or available for treatment of HIV cryptosporidiosis. [MMWR March 9, 1984; Rhone-Poulenc Rorer Pharmaceuticals]
Imipramine hydrochloride [USAN 1997]
Treatment of depression. [PDR 1997]
HIVAC-1e [J Clin Immunol 1992 Nov;12(6)]
Prevention of AIDS. [J Clin Immunol 1992 Nov;12(6)]
Vidarabine [USAN 1997]
IV or topical antiviral drug active against herpes simplex and varicella-zoster (VZV) viruses. Used to treat HSV (herpes simplex virus) encephalitis; neonatal encephalitis, infections of the skin, eyes, mouth, disseminated HSV and VZV infections with visceral involvement, and herpes zoster (shingles) due to reactivated VZV infections in immunosuppressed patients. [AmFAR Tx Dir 1997;8(3)]
Oxazepam [USAN 1997]
AIDS-related depression. [NIAID ACTG 124]
Allopurinol [USAN 1997]
Especially useful in preventing hyperuricemia and uric acid nephropathy resulting from tissue breakdown after cancer chemotherapy or radiation therapy. [AHFS Drug Information 1997]
Inosine pranobex [USAN 1997]
Primary HIV infection: Persistent generalized lymphadenopathy and ARC. [NIAID NS 403]
Interferon beta [AHFS Drug Information 1995]
Kaposi's sarcoma; primary HIV infection; cytomegalovirus (CMV) retinitis. Received licensure July 23, 1993. [Int Conf AIDS 1992 Jul 19-24;8(2); Ann Int Med 1990 Apr 15;112; Betaferon Patient Info Line Last Updated July 30, 1993]
Probenecid [USAN 1997]
Possible use in reducing the glucuronidation of zidovudine (azidothymidine (AZT)), thereby reducing the amount of AZT needed. [USP DI 1996]
Quinine Sulfate [USAN 1997]
Possible use in reducing the amount of AZT needed for treating patients with symptomatic HIV infection (AIDS or symptomatic AIDS-related complex (ARC)), via impairment of renal AZT elimination. The combination of quinine sulfate and clindamycin may be useful in the treatment of cryptosporidiosis. [Second International Conference on AIDS 1986 Paris; AHFS Drug Information 1997]
3'-Azido-2',3'-dideoxyuridine [USP DI 1995]
Primary HIV infection. [NIAID 89 CC-62]
Methylprednisolone [USAN 1997]
Used in conjunction with TMP/SMX (trimethoprim-sulfamethoxazole) or alternative regimens at the beginning of treatment of an acute episode of moderate to servere Pneumocystis carinii pneumonia. [AmFAR Tx Dir 1997;8(3)]
Flucytosine [USAN 1997]
Used with amphotericin B for treating acute cryptococcal meningitis. [AmFAR Tx Dir 1996;8(2)]
Cyclophosphamide [USAN 1997]
Approved for anti-cancer therapy, under investigation for lymphoma. [AmFAR Tx Dir 1997;8(3)]
Doxorubicin [USAN 1997]
Treatment of Kaposi's sarcoma. [AmFAR Tx Dir 1997;8(3)]
Vincristine [Merck Index 1996]
Under investigation for the treatment of Kaposi's sarcoma and lymphoma. [AmFAR Tx Dir 1997;8(3)]
Bleomycin [USAN 1997]
Used alone or in combination chemotherapy for the palliative treatment of AIDS-related Kaposi's sarcoma. [AHFS Drug Information 1997]
Itraconazole [USAN 1997]
Treatment of fungal infections: blastomycosis, pulmonary and extrapulmonary; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis; aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or refractory to amphotericin B therapy; onychomycosis due to dermatophytes of the toenail. [PDR 1997]
Stavudine [USPD 1998]
Stavudine was approved by the FDA on 6/27/94 for the treatment of adults with HIV infection. The drug is now also approved for use in children. Stavudine is most effective when used in combination with other antiretroviral drugs such as ddI, 3TC and protease inhibitors. [AmFAR Tx Dir 1998;9(2); HHS Press Release, June 27, 1994]
Butyldeoxynojirimycin [MeSH]
Primary HIV infection. Trials in AIDS/ARC patients indicated that the drug had no significant effect on p24 antigen levels or CD4 cell counts. [AmFAR Tx Dir 1995;7(4)]
gp160 Vaccine (MicroGeneSys) [AmFAR Tx Dir 1993;6(3)]
Primary HIV infection. [AmFAR Tx Dir 1997;8(3)]
Peptide T [Merck Index 1996]
Primary HIV infection; studied as a treatment for HIV associated neuropathy and neuropsychiatric impairment. [AmFAR Tx Dir 1995;7(4)]
Dideoxyadenosine [Merck Index 1996]
Primary HIV infection. [USP DI 1995]
Cytarabine [USAN 1997]
Used primarily in combination with other drugs for the treatment of acute myelocytic leukemia. Under investigation for treatment of Progressive Multifocal Leukoencephalopathy (PML). [AmFAR Tx Dir 1997;8(3)]
Piritrexim isethionate [USAN 1997]
Pneumocystis carinii pneumonia (PCP). [USP DI 1995]
Dapsone [USAN 1997]
Dapsone has been used in conjunction with trimethoprim for the treatment of initial episodes of Pneumocystis carinii pneumonia; prophylactic therapy for the primary and secondary prevention of Pneumocystis carinii pneumonia. [AHFS Drug Information 1997]
Interferon Alfa-2b [USAN 1997]
Kaposi's sarcoma. FDA approved 11/21/88 for adult Kaposi's sarcoma. FDA approved 2/25/91 for chronic Non-A, Non-B hepatitis. [PDR 1997]
Interferon alfa-2a [USAN 1997]
Treatment of AIDS-related Kaposi's sarcoma. FDA approved 11/21/88 for Kaposi's sarcoma. [PDR 1997]
Sulfadoxine [USAN 1997]
The combination of pyrimethamine and sulfadoxine Fansidar is used in the prophylaxis of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis and in patients who cannot tolerate co-trimoxazole prophylaxis. [AHFS Drug Information 1997]
Tumor Necrosis Factor [Merck Index 1996]
Primary HIV infection; limited effectiveness against Kaposi's sarcoma. [J Acquir Immune Defic Syndr. 1989;2(3)]
Sulfamethoxazole [USAN 1997]
Used in formulation with trimethoprim for treatment and prophylaxis of Pneumocystis carinii pneumonia in AIDS patients. FDA approved Bactrim and Septra 6/23/81 for PCP treatment and approved 1/7/94 for PCP prophylaxis. [AHFS Drug Information 1995]
Trimethoprim [USAN 1997]
Used in combination with sulfamethoxazole or dapsone for treatment of Pneumocystis carinii pneumonia. FDA approved Bactrim and Septra 6/23/81 for PCP treatment and approved 1/7/94 for PCP prophylaxis. [AHFS Drug Information 1995]
Antigens, CD4 [Lancet 1990 May 12; Vol 335 No 8698]
Primary HIV infection. [J Acquir Immune Defic Syndr 1995; 9(2)]
Ribavirin [USAN 1997]
Primary HIV infection. [AHFS Drug Information 1995]
Pyrimethamine [USAN 1997]
Used in combination with dapsone as primary and secondary prophylaxis in treating Pneumocystis carinii pneumonia (PCP). Combined with a sulfonamide for toxoplasmosis treatment. FDA approved for toxoplasmosis. [AHFS Drug Information 1997]
Primaquine [Merck Index 1996]
When used with clindamycin, it is effective for acute Pneumocystis carinii pneumonia (PCP). [USP DI 1995]
Pentamidine [USAN 1997]
Pneumocystis carinii pneumonia (PCP). FDA approved 10/16/84 for PCP treatment (im and iv). FDA approved 6/15/89 for PCP prophylaxis (aerosol). [PDR 1995; FDA Office of AIDS and Special Health Issues]
Methotrexate [USAN 1997]
Use in mixed drug therapy of patients with AIDS-associated lymphoma. [NIAID ACTG 074]
Methadone hydrochloride [USAN 1997]
Maintenance therapy of AIDS patients who were former drug abusers. [NIAID ACTG 055]
Globulin, immune [USAN 1997]
Primary HIV infection - used for maintenance treatment of patients unable to produce sufficient IgG antibodies and patients with thrombocytopenia. Can prevent or modify certain infections in adult and pediatric patients. FDA Approved 12/27/93 in HIV-infected children as prophylactic therapy against certain bacterial infections. [USP DI 1995]
Aldesleukin [USAN 1995]
Enhancement of immune response in HIV infection. [NIAID ACTG 024]
Interferon gamma [Merck Index 1989]
Under investigation for treatment of Mycobacterium tuberculosis infection in HIV-positive people. [AmFAR Tx Dir 1996;8(2)]
Interferon alfa-n1 [USAN 1997]
Kaposi's sarcoma in selected patients, 18 years of age or older. [USP DI 1996]
Ganciclovir [USAN 1997]
Indicated in the treatment of CMV (cytomegalovirus) retinitis in immunocompromised individuals. FDA approved 6/26/89 for CMV retinitis. FDA approved oral ganciclovir for marketing 1/5/95. [PDR 1997]
Foscarnet sodium [USAN 1997]
FDA approved 9/27/91 for cytomegalovirus retinitis in AIDS patients. [AHFS Drug Information 1995; FDA Press Release]
Didanosine [USPD 1998]
Didanosine was the second antiretroviral agent approved by FDA for HIV infection (1991), originally for the treatment of adults with advanced HIV infection who have received prolonged prior treatment with AZT. FDA recently approved didanosine as a first line therapy against HIV when antiretroviral therapy is warranted. Current recommendations generally advise using agents such as didanosine as part of a potent three-drug combination. [AmFAR Tx Dir 1998;9(2)]
Zalcitabine [USPD 1998]
Zalcitabine was originally approved in combination with AZT in patients with no prior antiretroviral experience. FDA approved zalcitabine as monotherapy for HIV+ people who have experienced disease progression while receiving AZT, or who are intolerant to AZT. Zalcitabine monotherapy is not as effective as AZT/zalcitabine comination therapy in prolonging the life of treatment-naive patients. Current recommendations generally advise a three-drug combination including a protease inhibitor. [AmFAR Tx Dir 1998;9(2)]
Dextran sulfate [Merck Index 1989]
Treatment of HIV in AIDS patients. [NIAID ACTG 060; Int Conf AIDS 1989 Jun 4-9;5; USP DI 1996]
Dexamethasone [USAN 1997]
Acquired autoimmune hemolytic anemia. [PDR 1997]
Sargramostim [USAN 1997]
Used to correct or minimize HIV-associated neutropenia and/or drug-induced neutropenia(i.e., due to treatment with zidovudine, interferon alfa, or cytotoxic chemotherapy). Used to increase neutrophil counts in patients with CMV infection who develop neutropenia while on ganciclovir, and in patients with nonmalignant conditions who develop neutropenia while on myelosuppressive drugs. FDA approved 3/5/91 for cancer patients with lymphomas or leukemia who are receiving bone marrow transplants. [AHFS Drug Information 1996; HHS Press Release, June 27, 1994; Int Conf AIDS 1990 Jun 20-23;6(3)]
Clindamycin [USAN 1997]
Treatment of mild-moderate Pneumocystis carinii pneumonia (PCP) and toxoplasmosis in AIDS patients. [AHFS Drug Information 1996]
AS-101 [AmFAR Tx Dir May, 1989]
Treatment of patients with low CD4 cells and HIV infection. [NIAID ACTG 046]
AL 721 [Merck Index 1989]
Persistent generalized lymphadenopathy (PGL) and symptomatic HIV infection. [NIAID ACTG 022]
Acyclovir [USAN 1997]
Initial treatment and management of recurrent Herpes virus (genitalis; simplex; zoster) infections and chickenpox infections in immunocompromised patients. [PDR 1997; USP DI 1996]
Acetaminophen [USAN 1997]
Treatment of mild to moderate fever and pain. [AHFS Drug Information 1996]
Amphotericin B [USAN 1997]
Acute cryptococcal meningitis. [AHFS Drug Information 1996]
Fluconazole [USAN 1997]
FDA approved 1/29/90 for the treatment of cryptococcal meningitis and oropharyngeal and esophageal candidiasis. [PDR 1995]
Zidovudine [USPD 1998]
Zidovudine is approved for the treatment of all HIV positive people with a CD4 count less than 500. Results of numerous clinical trials indicate that zidovudine is most effective when used in combination with other antiretroviral drugs. At its peak effectiveness in treatment-naive patients, zidovudine reduces HIV RNA levels by roughly 70%, and as a monotherapy cannot control viral replication in the majority of HIV infected patients. [AmFAR Tx Dir 1998;9(2)]
Cysteamine [USAN 1997]
Primary HIV infection. [Int Conf AIDS 1993 Jun 6-11;9(1)]
Leucovorin calcium [USAN 1997]
Prevention of mucositis and bone marrow toxicity associated with Trimetrexate when the latter is used for treatment of Pneumocystis carinii pneumonia (PCP) in AIDS patients. [NIAID ACTG 039]
Ampligen [Merck Index 1996]
Primary HIV infection (stimulation of immune system). [NIAID ACTG 054]
©1999. AEGIS.
=======================================================
■AEGIS Publications●U.S. Government★政府系機関の出版物
●
Centers for Disease Control
AIDS Daily Summary, CDC National AIDS Clearinghouse
CDC Emerging Infectious Diseases, Centers for Disease Control
CDC HIV/AIDS Fact Sheets, CDC National AIDS Clearinghouse
CDC Hotline Training Bulletins, CDC National AIDS Hotline
CDC Morbidity And Mortality Weekly Report Centers for Disease Control
CDC HIV/AIDS Surveillance Reports, Centers for Disease Control
● Food and Drug Administration
Approved Therapies for HIV/AIDS, or AIDS-related Conditions. - August 28, 1998.
● National Library of Medicine
AIDSLINE, National Library Of Medicine
NLM Drug Fact Sheets, ACTIS - National Library Of Medicine
NLM Trials, ACTIS - National Library of Medicine
● National Institute for Allergy and Infectious Disease
NIAID Agenda, National Institute for Allergy and Infectious Disease
NIAID HIV/AIDS Fact Sheets, National Institute for Allergy and Infectious Disease
●
Veterans Administration
AIDS Information Newsletter, Veterans Administration★リンク切れ
©1999. AEGIS.
=======================================================
●NIAID HIV/AIDS Fact Sheets, National Institute for Allergy and Infectious Disease
The NIAID Fact Sheets (NIAID) Series is prepared by the Office of Communications, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Table of Contents
1997 Publications
1995 Publications
-------------------------
●(NIAID) HIV Statistics
Office of Communications, National Institute of Allergy and Infectious Disease - July, 1998
(NIAID) HIV Prevention Efficacy Trials
Office of Communications, National Institute of Allergy and Infectious Disease - March, 1998
(NIAID) NIAID AIDS Vaccine Evaluation Units
Office of Communications, National Institute of Allergy and Infectious Disease - March, 1998
=======================================================
■■●HIV - AIDS Reference - AEGIS
HIV Reference
● HIV Reference: General
Glossary Of HIV Terms
"AIDS" or "HIV Disease"
Not everybody with HIV has "AIDS." This fact sheet explains the difference.
● HIV Reference: Patient
Day One.
If you just found out you have HIV, start with DAY ONE.
Treatment Strategy
When to start, when to change ... the latest information in plain English.
Drug Fact Sheets
The latest list of anti-HIV drugs approved for use in the United States. This is somewhat technical in nature. It is from the National Library of Medicine (U.S.).
Clinical Trials Finder.
Our award-winning "wizard" to help you find a nearby clinical trial.
● HIV Reference: Science
The HIV Life Cycle
A pictorial trip through the life cycle of the Human Immunovirus (HIV), the virus that causes "AIDS."
AIDSLINE
A huge collection of scientific abstracts and citations from the National Library of Medicine. Basically... if there was a technical article published on an HIV-related topic, there is an abstract of it in AIDSLINE.
● HIV Reference: History
"So little time..."
A year-by-year timeline of the epidemic -- What did they know? -- When did they know it?
● HIV Reference: Statistics
CDC HIV/AIDS Surveillance Reports
HIV/AIDS Surveillance Reports - 1993 to present.
Elsewhere on the Internet
Statistics: The Global Epidemic
The Joint United Nations Programme on HIV/AIDS, 1998
The United States Epidemic
HIV/AIDS Surveillance Reports from the Centers for Disease Control and Prevention
Adult/Adolescent AIDS Cases by Exposure Category, through 1997
This Powerpoint slide show from the CDC, presented by HIVInfoWeb, covers Adult/Adolescent AIDS Cases by Exposure Category, through 1997.
HIV Infection in Adolescents 13-19- Year Olds in 1997
This Powerpoint slide show from the CDC, presented by HIVInfoWeb, covers HIV Infection in Adolescents 13-19- Year Olds in 1997
Perinatally Transmitted AIDS Cases through 1997
This Powerpoint slide show from the CDC, presented by HIVInfoWeb, covers Perinatally Transmitted AIDS Cases through 1997.
● HIV Reference: Finding Printed Information
ÆGIS has an extensive library of abstracts of printed material. You'll see a summary of the material and information on how to get a copy.